<!--?xml version="1.0" encoding="UTF-8"?--><doc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" zoom="100" apt_id="1" id="doc_1"><mdata projectname="OUP" category="NARGAB" apt_id="2" id="mdata_2"><mta name="article-type" apt_id="3" id="mta_3">research-article</mta><mta name="publisher-id" apt_id="4" id="mta_4">lqaf053</mta><mta name="category-oup-series" apt_id="5" id="mta_5">NA</mta><mta name="category-subject-doi" apt_id="6" id="mta_6">NA</mta><mta name="category-taxonomy-collection" apt_id="7" id="mta_7">AcademicSubjects/SCI00030; AcademicSubjects/SCI00980; AcademicSubjects/SCI01060; AcademicSubjects/SCI01140; AcademicSubjects/SCI01180</mta><mta name="category-taxonomy-collection1" apt_id="8" id="mta_8">NA</mta><mta name="doi" apt_id="9" id="mta_9">10.1093/nargab/lqaf053</mta><mta name="supplementary-material-label" id="mta_10" apt_id="10">Graphical Abstract Figure.</mta><mta name="supplementary-material-caption" apt_id="11" id="mta_11">bbbbbbbb</mta><mta name="supplementary-material-graphic" label="image" apt_id="12" id="mta_12">lqaf053_gra.jpg</mta><mta name="pub-date-ppub" apt_id="13" id="mta_13">00-00-2025</mta><mta name="pub-date-epub" apt_id="14" id="mta_14">00-00-2025</mta><mta name="pub-date-collection" apt_id="15" id="mta_15">00-00-2025</mta><mta name="cover-date" apt_id="16" id="mta_16">00-2025</mta><mta name="volume" apt_id="17" id="mta_17">0</mta><mta name="issue" apt_id="18" id="mta_18">0</mta><mta name="fpage" apt_id="19" id="mta_19">1</mta><mta name="lpage" apt_id="20" id="mta_20">0</mta><mta name="elocation-id" apt_id="21" id="mta_21">00</mta><mta name="copyright-statement" apt_id="22" id="mta_22">© The Author(s) 2025. Published by Oxford University Press on behalf of NAR Genomics and Bioinformatics. <!--?break ?-->This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</mta><mta name="copyright-year" apt_id="23" id="mta_23">2025</mta><mta name="corrected-typeset" apt_id="24" id="mta_24">DD-MM-YYYY</mta><mta name="meta-name" exinfo="M1" apt_id="25" id="mta_25">edited-state</mta><mta name="meta-value" apt_id="26" id="mta_26">corrected-proof</mta><mta name="meta-name" exinfo="M2" apt_id="27" id="mta_27">article-lifecycle</mta><mta name="meta-value" apt_id="28" id="mta_28">PAP</mta><mta name="self-uri" exinfo="" apt_id="29" id="mta_29">lqaf053.pdf</mta><mta name="feature-fig-label-1" apt_id="30" id="mta_30">NA</mta><mta name="feature-fig-image-1" exinfo="IMG" apt_id="31" id="mta_31">NA</mta><mta name="feature-fig-label-2" apt_id="32" id="mta_32">NA</mta><mta name="feature-fig-image-2" exinfo="IMG" apt_id="33" id="mta_33">NA</mta><mta name="feature-fig-label-3" apt_id="34" id="mta_34">NA</mta><mta name="feature-fig-image-3" exinfo="IMG" apt_id="35" id="mta_35">NA</mta><mta name="source-wc" apt_id="36" id="mta_36">500</mta><mta name="non-printing-chars" apt_id="37" id="mta_37">false</mta><mta name="display-buttons" apt_id="38" id="mta_38">true</mta></mdata><fm apt_id="39" id="fm_39"><lrh title="Left Running Head" apt_id="40" id="lrh_40">Yazdani <i apt_id="41" id="i_41">et al.</i></lrh><rrh title="Right Running Head" apt_id="42" id="rrh_42"><query><button type="button" title="Copy Editor to Author-AU: Please check and provide Recto_(RRH)." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="1" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">1</span></button></query></rrh><dochead title="Doc Head" apt_id="45" id="dochead_45">Standard Article</dochead><ti title="Document Title" apt_id="46" id="ti_46">Novel treatment-specific causal biomarkers for colorectal cancer by omics integration<query><button type="button" title="Copy Editor to Author-AU: If your manuscript has figures or text from other sources, please ensure you have permission from the copyright holder. Also ensure that the copyright owner is properly credited, for instance in the figure legends. Make any changes directly in the text. For any questions about permissions, contact jnls.author.support@oup.com." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="2" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">2</span></button></query><query><button type="button" title="Copy Editor to Author-AU: CE: It is mandatory to insert a query for the author if any grammatical and stylistic changes are made in the title of the paper. Please insert an author query for the changes made in the title." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="3" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">3</span></button></query> </ti><aug title="Authors" sep=", " lsep="" apt_id="51" id="aug_51"><au suffix="1,2,*" rid="99 109 218" orcid="https://orcid.org/0000-0002-1243-6317" apt_id="52" id="au_52"><f title="First name" apt_id="53" id="f_53">Akram</f><s title="Surname" apt_id="54" id="s_54">Yazdani</s></au><au suffix="3" rid="117" apt_id="55" id="au_55"><f title="First name" apt_id="56" id="f_56">Azam</f><s title="Surname" apt_id="57" id="s_57">Yazdani</s></au><au suffix="4" rid="124" apt_id="58" id="au_58"><f title="First name" apt_id="59" id="f_59">Raul</f><s title="Surname" apt_id="60" id="s_60">Mendez-Giraldez</s></au><au suffix="5" rid="131" apt_id="61" id="au_61"><f title="First name" apt_id="62" id="f_62">Gianluigi</f><s title="Surname" apt_id="63" id="s_63">Pillonetto</s></au><au suffix="6" rid="137" apt_id="64" id="au_64"><f title="First name" apt_id="65" id="f_65">Esmat</f><s title="Surname" apt_id="66" id="s_66">Samiei</s></au><au suffix="7" rid="142" apt_id="67" id="au_67"><f title="First name" apt_id="68" id="f_68">Reza</f><s title="Surname" apt_id="69" id="s_69">Hadi</s></au><au suffix="8" rid="148" apt_id="70" id="au_70"><f title="First name" apt_id="71" id="f_71">Heinz-Josef</f><s title="Surname" apt_id="72" id="s_72">Lenz</s></au><au suffix="9" rid="155" apt_id="73" id="au_73"><f title="First name" apt_id="74" id="f_74">Alan P.</f><s title="Surname" apt_id="75" id="s_75">Venook</s></au><au suffix="10" rid="162" apt_id="76" id="au_76"><f title="First name" apt_id="77" id="f_77">Ahmad</f><s title="Surname" apt_id="78" id="s_78">Samiei</s></au><au suffix="11" rid="169" apt_id="79" id="au_79"><f title="First name" apt_id="80" id="f_80">Andrew B.</f><s title="Surname" apt_id="81" id="s_81">Nixon</s></au><au suffix="12" rid="176" apt_id="82" id="au_82"><f title="First name" apt_id="83" id="f_83">Joseph A.</f><s title="Surname" apt_id="84" id="s_84">Lucci</s><suffix title="Suffix" apt_id="85" id="suffix_85">3rd</suffix></au><au suffix="13,14" rid="183 190" apt_id="86" id="au_86"><f title="First name" apt_id="87" id="f_87">Scott</f><s title="Surname" apt_id="88" id="s_88">Kopetz</s></au><au suffix="15" rid="197" apt_id="89" id="au_89"><f title="First name" apt_id="90" id="f_90">Monica M.</f><s title="Surname" apt_id="91" id="s_91">Bertagnolli</s></au><au suffix="16,17" rid="204 210" orcid="https://orcid.org/0000-0001-9827-2247" apt_id="92" id="au_92"><f title="First name" apt_id="93" id="f_93">Charles M.</f><s title="Surname" apt_id="94" id="s_94">Perou</s></au><au suffix="1" rid="99" apt_id="95" id="au_95"><f title="First name" apt_id="96" id="f_96">Federico</f><s title="Surname" apt_id="97" id="s_97">Innocenti</s></au></aug><affg type="arabic" apt_id="98" id="affg_98"><aff id="aff_99" sno="1" type="arabic" apt_id="99"><org title="Organization" apt_id="100" id="org_100">Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill</org>, <str title="Street" apt_id="101" id="str_101">NC</str>, <cny title="Country" apt_id="102" id="cny_102">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="4" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">4</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="5" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">5</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please check the spelling and accuracy of all author names and affiliations, particularly for any co-authors. Also check that author surnames are correctly highlighted. This is to ensure that forenames and surnames are tagged correctly for online indexing. Incorrect names and affiliations may lead to an author not being credited for their work by funders, institutions, or other third parties. Make any changes directly in the text. Note that changes to your authorship list (adding or removing authors, changing designation of corresponding author) require additional approvals. Email jnls.author.support@oup.com if this is required." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="6" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">6</span></button></query></aff><aff id="aff_109" sno="2" type="arabic" apt_id="109"><org title="Organization" apt_id="110" id="org_110">McGovern Medical School, University of Texas Health Science Center at Houston</org>, <str title="Street" apt_id="111" id="str_111">TX</str>, <cny title="Country" apt_id="112" id="cny_112">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="7" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">7</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please provide department for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="8" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">8</span></button></query></aff><aff id="aff_117" sno="3" type="arabic" apt_id="117"><org title="Organization" apt_id="118" id="org_118">Division of Preventive Medicine, Department of Medicine, Brigham &amp; Women's Hospital, Harvard Medical School</org>, <str title="Street" apt_id="119" id="str_119">Boston</str>, <str title="Street" apt_id="120" id="str_120">MA</str>, <cny title="Country" apt_id="121" id="cny_121">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="9" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">9</span></button></query></aff><aff id="aff_124" sno="4" type="arabic" apt_id="124"><org title="Organization" apt_id="125" id="org_125">Biostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences</org>, <str title="Street" apt_id="126" id="str_126">Durham</str>, <str title="Street" apt_id="127" id="str_127">NC</str>, <cny title="Country" apt_id="128" id="cny_128">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide institute/postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="10" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">10</span></button></query></aff><aff id="aff_131" sno="5" type="arabic" apt_id="131"><org title="Organization" apt_id="132" id="org_132">Department of Information Engineering, University of Padova</org>, <str title="Street" apt_id="133" id="str_133">Padova</str>, <cny title="Country" apt_id="134" id="cny_134">Italy</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="11" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">11</span></button></query></aff><aff id="aff_137" sno="6" type="arabic" apt_id="137">Gamelectronic, <str title="Street" apt_id="138" id="str_138">Tehran</str>, <cny title="Country" apt_id="139" id="cny_139">Iran</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide institute/postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="12" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">12</span></button></query></aff><aff id="aff_142" sno="7" type="arabic" apt_id="142"><org title="Organization" apt_id="143" id="org_143">School of Mathematics, University of Science and Technology of Iran</org>, <str title="Street" apt_id="144" id="str_144">Tehran</str>, <cny title="Country" apt_id="145" id="cny_145">Iran</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="13" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">13</span></button></query></aff><aff id="aff_148" sno="8" type="arabic" apt_id="148"><org title="Organization" apt_id="149" id="org_149">USC Norris Comprehensive Cancer Center</org>, <str title="Street" apt_id="150" id="str_150">Los Angeles</str>, <str title="Street" apt_id="151" id="str_151">CA</str>, <cny title="Country" apt_id="152" id="cny_152">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide institute/postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="14" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">14</span></button></query></aff><aff id="aff_155" sno="9" type="arabic" apt_id="155"><org title="Organization" apt_id="156" id="org_156">University of California at San Francisco</org>, <str title="Street" apt_id="157" id="str_157">San Francisco</str>, <str title="Street" apt_id="158" id="str_158">CA</str>, <cny title="Country" apt_id="159" id="cny_159">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="15" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">15</span></button></query></aff><aff id="aff_162" sno="10" type="arabic" apt_id="162"><org title="Organization" apt_id="163" id="org_163">Division of Pulmonary Medicine, Boston Children's Hospital</org>, <str title="Street" apt_id="164" id="str_164">Boston</str>, <str title="Street" apt_id="165" id="str_165">MA</str>, <cny title="Country" apt_id="166" id="cny_166">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="16" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">16</span></button></query></aff><aff id="aff_169" sno="11" type="arabic" apt_id="169"><org title="Organization" apt_id="170" id="org_170">Duke Center for Cancer Immunotherapy, Duke University</org>, <str title="Street" apt_id="171" id="str_171">Durham</str>, <str title="Street" apt_id="172" id="str_172">NC</str>, <cny title="Country" apt_id="173" id="cny_173">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="17" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">17</span></button></query></aff><aff id="aff_176" sno="12" type="arabic" apt_id="176"><org title="Organization" apt_id="177" id="org_177">Department of Pharmacy, University of Texas Heath-Memorial Hermann Cancer Center</org>, <str title="Street" apt_id="178" id="str_178">Houston</str>, <str title="Street" apt_id="179" id="str_179">TX</str>, <cny title="Country" apt_id="180" id="cny_180">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="18" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">18</span></button></query></aff><aff id="aff_183" sno="13" type="arabic" apt_id="183"><org title="Organization" apt_id="184" id="org_184">Departments of Gastrointestinal Medical Oncology, University of Texas M. D. Anderson Cancer Center</org>, <str title="Street" apt_id="185" id="str_185">Houston</str>, <str title="Street" apt_id="186" id="str_186">TX</str>, <cny title="Country" apt_id="187" id="cny_187">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="19" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">19</span></button></query></aff><aff id="aff_190" sno="14" type="arabic" apt_id="190"><org title="Organization" apt_id="191" id="org_191">Departments of Surgical Oncology, University of Texas M. D. Anderson Cancer Center</org>, <str title="Street" apt_id="192" id="str_192">Houston</str>, <str title="Street" apt_id="193" id="str_193">TX</str>, <cny title="Country" apt_id="194" id="cny_194">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="20" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">20</span></button></query></aff><aff id="aff_197" sno="15" type="arabic" apt_id="197"><org title="Organization" apt_id="198" id="org_198">Dana-Farber/ Partners Cancer Care, Harvard Medical School</org>, <str title="Street" apt_id="199" id="str_199">Boston</str>, <str title="Street" apt_id="200" id="str_200">MA</str>, <cny title="Country" apt_id="201" id="cny_201">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide institute/postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="21" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">21</span></button></query></aff><aff id="aff_204" sno="16" type="arabic" apt_id="204"><org title="Organization" apt_id="205" id="org_205">Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill</org>, <str title="Street" apt_id="206" id="str_206">NC</str>, <cny title="Country" apt_id="207" id="cny_207">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code/city for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="22" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">22</span></button></query></aff><aff id="aff_210" sno="17" type="arabic" apt_id="210"><org title="Organization" apt_id="211" id="org_211">Department of Genetics, School of Medicine, University of North Carolina at Chapel Hill</org>, <str title="Street" apt_id="212" id="str_212">Chapel Hill</str>, <str title="Street" apt_id="213" id="str_213">NC</str>, <cny title="Country" apt_id="214" id="cny_214">United States</cny><query><button type="button" title="Copy Editor to Author-AU: Please provide postal code for affiliation directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="23" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">23</span></button></query></aff></affg><coraddg type="symbol" apt_id="217" id="coraddg_217"><coradd title="Cor Address" id="coradd_218" sno="*" type="symbol" apt_id="218">To whom correspondence should be addressed. Email: <email href="mailto:akramyazdani16@gmail.com" title="e-Mail" apt_id="219" id="email_219">akramyazdani16@gmail.com</email><query><button type="button" title="Copy Editor to Author-AU: CE: phone is missing, please provide." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="24" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">24</span></button></query><query><button type="button" title="Copy Editor to Author-AU: CE: Fax is missing, please provide." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="25" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">25</span></button></query></coradd></coraddg><hsy title="History" sep=";" id="hsy_224" apt_id="224"><re apt_id="225" id="re_225">July 17, 2024</re><rsd apt_id="226" id="rsd_226">April 8, 2025</rsd><edd apt_id="227" id="edd_227">April 14, 2025</edd></hsy><absg apt_id="228" id="absg_228"><ti title="Abstract Head" apt_id="229" id="ti_229">Abstract</ti>
<p t="fl" title="Paragraph No Indent" apt_id="230" id="p_230">While monoclonal antibody-based targeted therapies have substantially improved progression-free survival in cancer patients, the variability in individual responses poses a significant challenge in patient care. Therefore, identifying cancer subtypes and their associated biomarkers is required for assigning effective treatment. In this study, we integrated genotype and pre-treatment tissue RNA-seq data and identified biomarkers causally associated with the overall survival (OS) of colorectal cancer (CRC) patients treated with either cetuximab or bevacizumab. We performed enrichment analysis for specific consensus molecular subtypes (CMS) of colorectal cancer and evaluated differential expression of identified genes using paired tumor and normal tissue from an external cohort. In addition, we replicated the causal effect of these genes on OS using validation cohort and assessed their association with the Cancer Genome Atlas Program data as an external cohort. One of the replicated findings was <i apt_id="231" id="i_231">WDR62</i>, whose overexpression shortened OS of patients treated with cetuximab. Enrichment of its over expression in CMS1 and low expression in CMS4 suggests that patients with CMS4 subtype may derive greater benefit from cetuximab. In summary, this study highlights the importance of integrating different omics data for identifying promising biomarkers specific to a treatment or a cancer subtype<query><button type="button" title="Copy Editor to Author-AU: The abstract has been edited as a single paragraph to match journal style. Please edit, if necessary, directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="26" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">26</span></button></query>.<query><button type="button" title="Copy Editor to Author-AU: Please provide a short caption for the graphical abstract." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="27" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">27</span></button></query></p>
</absg><absg exinfo="graphical" apt_id="236" id="absg_236"><ti title="Abstract Head" apt_id="237" id="ti_237">Graphical Abstract</ti><fig id="fig_238" apt_id="238"><ti title="Abstract Head" apt_id="239" id="ti_239">aaaaaa</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_gra.jpg" title="Figure" apt_id="240" id="img_240" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="241" id="button_241"><i class="fa-solid fa-pen-to-square" apt_id="242" id="i_242"></i></button></fig> </absg></fm><bdy apt_id="243" id="bdy_243"><sect1 id="sect1_244" sec-type="intro" apt_id="244"><ti title="Heading 1" apt_id="245" id="ti_245">Introduction</ti>
<p t="fl" title="Paragraph No Indent" apt_id="246" id="p_246">While targeted therapies utilizing monoclonal antibodies have improved progression-free survival in patients, the pursuit of more effective cancer treatments remains a top priority. What complicates this pursuit is the diverse range of patient responses to existing therapies, which manifests as a significant obstacle in understanding the underlying variability in clinical outcomes [<bibcit rid="647" title="bibcit" href="#" contenteditable="false" id="bibcit_247" sno="1" apt_id="247">1</bibcit>]<query><button type="button" title="Copy Editor to Author-AU: Please note that the reference citations in the  text have been reordered to be in sequential order. Check and correct where necessary directly in the references." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="28" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">28</span></button></query>. Therefore, the key to addressing this challenge is identifying cancer subtypes and their associated biomarkers, allowing for precision in treatment strategies and ultimately leading to enhanced patient outcomes and a personalized approach to cancer care.</p>
<p t="i" title="Paragraph Indented" apt_id="250" id="p_250">In colorectal cancer (CRC), molecular classifications have provided valuable insights into disease biology. One such classification is the transcriptomics-based consensus molecular subtype (CMS), which categorizes CRC into four groups, CMS1 (microsatellite instability immune), CMS2 (canonical), CMS3 (metabolic), and CMS4 (mesenchymal), based on the underlying biology of the disease rather than relying solely on clinical outcomes [<bibcit rid="665" title="bibcit" href="#" contenteditable="false" id="bibcit_251" sno="2" apt_id="251">2</bibcit>, <bibcit rid="683" title="bibcit" href="#" contenteditable="false" id="bibcit_252" sno="3" apt_id="252">3</bibcit>]. While these classifications have been instrumental in stratifying patients, the subtypes still exhibit molecular heterogeneity and do not fully capture the complexity of CRC. As a result, several key aspects of CRC progression and treatment response remain unresolved [<bibcit rid="702" title="bibcit" href="#" contenteditable="false" id="bibcit_253" sno="4" apt_id="253">4</bibcit>], highlighting the need to move beyond broad classifications to identify more precise molecular determinants that drive differential treatment responses in CRC. To address this gap, our study aims to identify pre-treatment biomarkers with a causal impact on OS in CRC patients, ultimately guiding precision treatment strategies. We hypothesize that gene expression profiles contribute to differential treatment responses. By integrating genomic and transcriptomic data, we seek to identify these biomarkers and elucidate their role in modulating treatment response.</p>
<p t="i" title="Paragraph Indented" apt_id="254" id="p_254">To this end, we analyzed data from a randomized phase III trial (CALGB/SWOG 80405) involving 1 284 patients with KRAS wild-type advanced or metastatic CRC. These patients were treated with either cetuximab or bevacizumab in combination with chemotherapy (FOLFOX or FOLFIRI). Cetuximab targets the epidermal growth factor receptor (EGFR) and influences immune cells, including natural killer (NK) cells and macrophages [<bibcit rid="720" title="bibcit" href="#" contenteditable="false" id="bibcit_255" sno="5" apt_id="255">5</bibcit>], while bevacizumab targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis. Although, the clinical outcomes of this study did not reveal a significant difference in overall survival (OS) between these two treatments when used as first-line therapy [<bibcit rid="737" title="bibcit" href="#" contenteditable="false" id="bibcit_256" sno="6" apt_id="256">6</bibcit>], the distinct biological pathways they affect suggest that different molecular mechanisms underlie treatment response and resistance. Hence, investigating these mechanisms at the molecular level is crucial to identifying predictive biomarkers and improving precision treatment strategies.</p>
<p t="i" title="Paragraph Indented" apt_id="257" id="p_257">We analyzed gene expression (RNA-seq) data to investigate its influence on treatment response, segmenting our dataset into a discovery cohort and a validation cohort based on gene expression availability (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="258" id="url_258">Supplementary Fig. S1</url>, <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="259" id="url_259">Supplementary Table S1</url>). In the discovery cohort, comprising 273 samples with RNA-seq data (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="260" id="url_260">Supplementary Fig. S2</url>), we conducted one-sample Mendelian randomization (MR) analysis, integrating germline genotype, RNA-seq, and treatment-specific OS data. In the validation cohort, which included 602 patients with available germline genotype data and clinical outcomes, including OS, we performed a two-sample MR analysis to replicate the results obtained in the discovery cohort. To further validate our results, we incorporated external cohorts, including The Cancer Genome Atlas (TCGA) data and the GSE146889 dataset sourced from the Gene Expression Omnibus database. In addition, we examined the association between the identified biomarkers and CMS subtypes to refine our understanding of their role in modulating treatment response across distinct patient groups. This integrative approach allowed us to link molecular features with clinical outcomes, providing insights into the biological mechanisms driving differential responses to therapy and aiding in the development of precision oncology strategies.</p>
</sect1><sect1 id="sect1_261" sec-type="materials|methods" apt_id="261"><ti title="Heading 1" apt_id="262" id="ti_262">Materials and methods</ti><sect2 id="sect2_263" apt_id="263"><ti title="Heading 2" apt_id="264" id="ti_264">Ethical statement</ti>
<p t="fl" title="Paragraph No Indent" apt_id="265" id="p_265">While institutional review board approval was required at all participating centers and all participating patients provided written informed consent, this study has used deidentified samples.</p>
</sect2><sect2 id="sect2_266" apt_id="266"><ti title="Heading 2" apt_id="267" id="ti_267">Data</ti>
<p t="fl" title="Paragraph No Indent" apt_id="268" id="p_268">Patients in this study were drawn from the Cancer and Leukemia Group B (CALGB; now a part of the Alliance for Clinical Trials in Oncology) and SWOG 80405 (Alliance) trial. The trial was initiated in September 2005 with a total of 2 326 patients randomized to the three treatment arms (bevacizumab, cetuximab, or their combination in addition to chemotherapy with FOLFIRI or FOLFOX).</p>
<sect3 id="sect3_269" apt_id="269"><ti title="Heading 3" apt_id="270" id="ti_270">Genotyping</ti>
<p t="fl" title="Paragraph No Indent" apt_id="271" id="p_271">DNA was extracted from peripheral blood. The first genotyping batch was performed on the Illumina HumanOmniExpress-12v1 platform at the Riken Institute (Tokyo, Japan) and included 731 412 genotyped variants. The second genotyping batch was performed on the Illumina HumanOmniExpress-8v1 and included 964 193 single nucleotide polymorphisms (SNPs). A total of 719 461 SNPs from HapMap from batch 1 were also on the chip from batch 2. The QC was performed to remove SNPs with mismatched annotation between the two platforms, genotyping call rates less than 99%, departure from Hardy–Weinberg equilibrium (<i apt_id="272" id="i_272">P </i>&lt; 10<sup apt_id="273" id="sup_273">−8</sup>), allele frequencies less than 0.05, and individuals with genotyping call rate &lt; 0.90. Passing the filters, 540 021 SNPs genotyped for 1 165 samples remained [<bibcit rid="755" title="bibcit" href="#" contenteditable="false" id="bibcit_274" sno="7" apt_id="274">7</bibcit>].</p>
</sect3><sect3 id="sect3_275" apt_id="275"><ti title="Heading 3" apt_id="276" id="ti_276">Tumor RNA sequencing</ti>
<p t="fl" title="Paragraph No Indent" apt_id="277" id="p_277">Tumor RNA was extracted from formalin-fixed paraffin-embedded (FFPE) tumor blocks (96% primary, 2% metastatic, 2% unknown) from 584 CALGB/SWOG 80405 patients at the baseline. TruSeq RNA Access target enrichment and library preparation protocol was performed using 250 ng of template RNA. Sequencing was done using synthesis chemistry targeting 50 M reads with a read length of 2 × 100 bp per sample on the HiSeq 2500. Data processing was conducted using standard procedures [<bibcit rid="773" title="bibcit" href="#" contenteditable="false" id="bibcit_278" sno="8" apt_id="278">8</bibcit>].</p>
</sect3><sect3 id="sect3_279" apt_id="279"><ti title="Heading 3" apt_id="280" id="ti_280">Clinical outcomes and covariates</ti>
<p t="fl" title="Paragraph No Indent" apt_id="281" id="p_281">The primary endpoint of OS was calculated from the time of study entry to death or last known follow-up for those without reported death. The median follow-up duration for the 640 samples in the bevacizumab and cetuximab arms was 65.7 months (95% confidence interval, 63.5–70). In addition, BRAF V600E and all RAS mutation status were determined by BEAMing (beads, emulsion, amplification, magnetics; Hamburg, Germany) technology [<bibcit rid="791" title="bibcit" href="#" contenteditable="false" id="bibcit_282" sno="9" apt_id="282">9</bibcit>] and included in the analysis as covariates in addition to age and gender.</p>
</sect3></sect2><sect2 id="sect2_283" apt_id="283"><ti title="Heading 2" apt_id="284" id="ti_284">Data preprocessing</ti>
<p t="fl" title="Paragraph No Indent" apt_id="285" id="p_285">Among 584 samples with RNA-seq data, 86% were European American, 9% African American, 5% from other ethnicities. Therefore, we focused on primary tumor samples from European American to avoid analysis being confounded due to population stratification. We excluded genes with low expression variation across samples (standard deviation &lt; 0.5) and genes with low counts across the samples (&gt; 30% zeros). The remaining was 8301 genes for the analysis, and we applied upper quartile normalization to make gene expression values comparable among different samples. We removed duplicated samples (n = 5) and tumors with low gene expression across the genome (&gt; 50% genes with zero counts, n = 1). We then transformed the RNA-seq data into the log2 scale for the analysis. We performed principal component analysis to assess for any potential technical and systematic variation or hidden population stratification in RNA-seq data (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="286" id="url_286">Supplementary Fig. S3</url>). To verify the self-reported gender, we applied k-mean clustering using the expression of genes in chromosome Y, resulting in 5 samples with mismatched biological gender and recorded gender [<bibcit rid="809" title="bibcit" href="#" contenteditable="false" id="bibcit_287" sno="10" apt_id="287">10</bibcit>] (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="288" id="url_288">Supplementary Fig. S4</url>).</p>
<p t="i" title="Paragraph Indented" apt_id="289" id="p_289">We used 1 055 tumor samples (European American), genotyped at 540 021 SNPs for imputation. We used phased haplotypes from the Haplotype Reference Consortium (HRC) panel through the Michigan server [<bibcit rid="827" title="bibcit" href="#" contenteditable="false" id="bibcit_290" sno="11" apt_id="290">11</bibcit>]. Phasing was done using Eagle v2.4 algorithm [<bibcit rid="845" title="bibcit" href="#" contenteditable="false" id="bibcit_291" sno="12" apt_id="291">12</bibcit>]. The HRC panel combines sequence data across &gt; 32 000 individuals from &gt; 20 medical sequencing studies. Through imputation, we generated genotypes for additional SNPs, and the final set of 5 539 144 common SNPs was selected based on imputation score (&gt; 0.7) and minor allele frequency (MAF) (&gt; 0.05). These imputed SNPs were used in all subsequent analyses.</p>
</sect2><sect2 id="sect2_292" apt_id="292"><ti title="Heading 2" apt_id="293" id="ti_293">Immune cell type abundance</ti>
<p t="fl" title="Paragraph No Indent" apt_id="294" id="p_294">Since the RNA-seq data in this study has been generated from heterogeneous tumor samples composed of multiple cell types, correcting for the abundance of different cell types in the data is crucial to avoid the analysis being confounded. We estimated the abundance of immune cell types in our RNA-seq data using CIBERSORTx [<bibcit rid="863" title="bibcit" href="#" contenteditable="false" id="bibcit_295" sno="13" apt_id="295">13</bibcit>] with the validated leukocyte gene signature matrix as a reference. We defined a cell phenotype to be enriched in our data if at most 30% of its estimated scores across samples are zero and its standard deviation is greater than 0.12. As a result, 9 hematopoietic cell phenotypes were enriched in our data: naive and memory B cells, plasma cells, CD8 + T cells, resting and activated memory CD4 + T cells, M0 and M2 macrophages, and activated mast cells [<bibcit rid="809" title="bibcit" href="#" contenteditable="false" id="bibcit_296" sno="10" apt_id="296">10</bibcit>]. These enriched cell type abundances (Data <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="297" id="url_297">Supplementary Table S1</url>) were used to adjust the gene expression levels in our downstream analysis.</p>
</sect2><sect2 id="sect2_298" apt_id="298"><ti title="Heading 2" apt_id="299" id="ti_299"><i apt_id="300" id="i_300">cis</i>-eQTL analysis</ti>
<p t="fl" title="Paragraph No Indent" apt_id="301" id="p_301">To identify germline genetic variants associated with tumor gene expression, we previously focused on <i apt_id="302" id="i_302">cis</i>-eQTL (Aguet <i apt_id="303" id="i_303">et al.</i>, 2017<query><button type="button" title="Copy Editor to Author-AU: Please note that the reference 'Aguet et al., 2017' is not listed in the reference  list. Please add it to the list and link the citation to the reference or delete the mention of the reference directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="29" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">29</span></button></query>; [<bibcit rid="882" title="bibcit" href="#" contenteditable="false" id="bibcit_306" sno="14" apt_id="306">14</bibcit>]). For all pairs of genes and SNPs within 1 Mb upstream and downstream of the gene’ transcription start site (TSS), we applied a linear regression model while accounting for covariates (gender, age, BRAF V600E mutations and all RAS mutation status, batch effects, enriched cell type abundances). We performed <i apt_id="307" id="i_307">cis</i>-eQTL mapping using FastQT [<bibcit rid="900" title="bibcit" href="#" contenteditable="false" id="bibcit_308" sno="15" apt_id="308">15</bibcit>]. We applied the adaptive permutation mode of FastQTL while setting for 10 000 permutations. Out of 8 301 genes analyzed, 352 were identified with at least one <i apt_id="309" id="i_309">cis</i>-eQTL at the gene level, meeting the threshold of an adjusted <i apt_id="310" id="i_310">p</i>-value &lt; 0.05. This analysis which evaluated the relationship of 33 209 829 <i apt_id="311" id="i_311">cis</i>-eQTL-gene pairs, has been published elsewhere [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_312" sno="16" apt_id="312">16</bibcit>] (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="313" id="url_313">Supplementary Figs S5</url>-<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="314" id="url_314">S6</url>). Hereafter, for simplicity, we use eQTL to refer to <i apt_id="315" id="i_315">cis</i>-eQTL.</p>
</sect2><sect2 id="sect2_316" apt_id="316"><ti title="Heading 2" apt_id="317" id="ti_317">Mendelian randomization (MR) study</ti>
<p t="fl" title="Paragraph No Indent" apt_id="318" id="p_318">We conduct one-sample MR analysis to identify gene expressions that have a causal relationship with OS, using genetic factors as instrumental variables (IVs). In this analysis, we focused on genes with eQTLs and consider these eQTLs as potential IV candidates. We then take the following steps to ensure the assumptions required for IVs are satisfied.</p>
<ol type="1" prefix="" suffix="." apt_id="319" id="ol_319">
<li apt_id="320" id="li_320">
<p t="fl" title="Paragraph No Indent" apt_id="321" id="p_321"><b apt_id="322" id="b_322">Gene-OS association:</b> To investigate if genes (<i apt_id="323" id="i_323">G</i>) with eQTL are associated with OS (i.e, the outcome), we applied multivariable time-variant additive hazard regression model.</p>
<eqn sub-type="" id="eqn_324" apt_id="324"><latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1151698001.gif" apt_id="325" id="latex_325"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1151698001.gif" apt_id="326" id="img_326" /><!--<?TeX \begin{equation*}h\left( {t{\rm{|}}X} \right) = {h_0}\left( t \right) + \gamma {\left( t \right)^T}Z\ + \theta {\left( t \right)^T}E + \beta {\left( t \right)^T}G\end{equation*}?>--></latex></eqn></li>
</ol>
<p t="i" title="Paragraph Indented" apt_id="327" id="p_327">Here, <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1570854038.gif" id="latex_328" apt_id="328"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1570854038.gif" apt_id="329" id="img_329" /><!--<?TeX $h( {t{\rm{|}}X} )$?>--></latex> is the hazard function, <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1990010075.gif" id="latex_330" apt_id="330"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1990010075.gif" apt_id="331" id="img_331" /><!--<?TeX ${h_0}( t )$?>--></latex> is the baseline hazard, <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_613054356.gif" id="latex_332" apt_id="332"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_613054356.gif" apt_id="333" id="img_333" /><!--<?TeX $\beta ( t )$?>--></latex> is a <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1802738321.gif" id="latex_334" apt_id="334"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1802738321.gif" apt_id="335" id="img_335" /><!--<?TeX $p \times 1$?>--></latex> time-varying coefficient vector. The model accounts for the set of covariates (Z) including gender, age, BRAF V600E mutations and all RAS mutation status and <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1451366430.gif" id="latex_336" apt_id="336"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1451366430.gif" apt_id="337" id="img_337" /><!--<?TeX $\gamma ( t )$?>--></latex> is a time-varying coefficient vectors for covariates. In addition, since our RNA-seq data is bulk, immune cell types present in the tumor microenvironment can influence the gene expression profiles, potentially introducing bias. Therefore, the model adjusts for the abundances of immune cell types (<i apt_id="338" id="i_338">E</i>) to minimize this bias while <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_74410711.gif" id="latex_339" apt_id="339"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_74410711.gif" apt_id="340" id="img_340" /><!--<?TeX $\theta ( t )$?>--></latex> represents their time-varying coefficient. This adjustment ensures that the associations between gene expression and overall survival (OS) more accurately reflect the tumor cells themselves, rather than being confounded by immune cell contributions.</p>
<p t="i" title="Paragraph Indented" apt_id="341" id="p_341">This additive hazard regression model relaxes the assumption of the time invariant effect of the genes on OS and allows for estimating causal effects [<bibcit rid="936" title="bibcit" href="#" contenteditable="false" id="bibcit_342" sno="17" apt_id="342">17</bibcit>]. Using this model, we conducted separate analysis for the patients under bevacizumab treatment and cetuximab treatment. To enhance the feasibility of conducting multivariable analysis and to prevent overfitting, we employed <i apt_id="343" id="i_343">k</i>-mean clustering and clustered all genes in 4 clusters [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_344" sno="16" apt_id="344">16</bibcit>]. Using these clusters, we divided the 352 genes into four groups and conducted multivariable analyses for each group, incorporating all genes with eQTLs within each cluster into the corresponding model. Gene associated with OS (<i apt_id="345" id="i_345">p</i>-value &lt; 0.1) were considered for causal study using the MR technique reviewed in the next steps.</p>
<ol type="1" prefix="" suffix="." apt_id="346" id="ol_346">
<li apt_id="347" id="li_347">
<p t="fl" title="Paragraph No Indent" apt_id="348" id="p_348"><b apt_id="349" id="b_349">Assessment of pleiotropy absence:</b> We conducted a GWAS and estimated the effect of IVs on OS via a Cox proportional hazard model while adjusting for covariates gender, age, tumor location, all-RAS, and KRAS mutation as well as the first principal component accounting for the batch effect (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="350" id="url_350">Supplementary Fig. S7</url>). The significance threshold in GWAS is typically set at a <i apt_id="351" id="i_351">p</i>-value of less than 5 × 10<sup apt_id="352" id="sup_352">−8</sup>. Any association above this threshold for IV-OS associations can be assumed as a lack of pleiotropy. However, we employed a stringent threshold of <i apt_id="353" id="i_353">p</i>-value &lt; 1 × 10<sup apt_id="354" id="sup_354">−4</sup> and excluded IVs with <i apt_id="355" id="i_355">p</i>-values &lt; 1 × 10<sup apt_id="356" id="sup_356">−4</sup> to ensure that the assumption of lack of pleiotropy holds.</p>
</li>
<li apt_id="357" id="li_357">
<p t="fl" title="Paragraph No Indent" apt_id="358" id="p_358"><b apt_id="359" id="b_359">Gene-OS causal association:</b> We evaluated the causal impact of associated genes with OS by predicting the expression level of each gene using its IVs. If the predicted expression value is associated with OS, the corresponding gene is considered as a putative cause of OS.</p>
</li>
</ol>
<p t="i" title="Paragraph Indented" apt_id="360" id="p_360">To predict the expression level of a gene, we selected SNPs associated with 352 gene from eQTL analysis, using a nominal <i apt_id="361" id="i_361">p</i>-value threshold of &lt; 0.05. The number of eQTLs can vary from just a few to several dozen across different genes. To generate independent IVs, we initially clustered the SNPs of the gene based on their pairwise correlation (r<sup apt_id="362" id="sup_362">2</sup> &gt; 0.1 within each cluster) using hierarchical clustering. We then selected one IV from each cluster as representative proxy to capture the genetic variation within the cluster. By selecting one IV as the proxy, we ensured that the chosen IVs for a gene were independent while reducing redundancy and minimizing the risk of overfitting in the predictive model. We then predicted the expression level of each gene (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_493566748.gif" id="latex_363" apt_id="363"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_493566748.gif" apt_id="364" id="img_364" /><!--<?TeX $\hat{g}$?>--></latex>) as follows</p>
<p t="i" title="Paragraph Indented" apt_id="365" id="p_365"><latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_912722785.gif" id="latex_366" apt_id="366"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_912722785.gif" apt_id="367" id="img_367" /><!--<?TeX ${\hat{g}_i} = \ {Q_i}\ {W_i}$?>--></latex>.</p>
<p t="i" title="Paragraph Indented" apt_id="368" id="p_368">Here <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_306294994.gif" id="latex_369" apt_id="369"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_306294994.gif" apt_id="370" id="img_370" /><!--<?TeX ${Q_i}$?>--></latex> is an <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_2102406750.gif" id="latex_371" apt_id="371"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_2102406750.gif" apt_id="372" id="img_372" /><!--<?TeX $n \times {p_i}$?>--></latex> matrix of IVs where <i apt_id="373" id="i_373">n</i> is the sample size and <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1495978959.gif" id="latex_374" apt_id="374"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1495978959.gif" apt_id="375" id="img_375" /><!--<?TeX ${p_i}$?>--></latex> is the number of IVs for <i apt_id="376" id="i_376">i</i>th gene (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1144607068.gif" id="latex_377" apt_id="377"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1144607068.gif" apt_id="378" id="img_378" /><!--<?TeX ${g_i}$?>--></latex>), and <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1915134996.gif" id="latex_379" apt_id="379"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1915134996.gif" apt_id="380" id="img_380" /><!--<?TeX ${W_i}$?>--></latex> is a <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_186807386.gif" id="latex_381" apt_id="381"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_186807386.gif" apt_id="382" id="img_382" /><!--<?TeX ${p_i} \times $?>--></latex>1 vector of the estimated coefficients from the eQTL analysis. If the correlation between predicted gene expression and the actual value exceeded 0.5, we investigated the gene-OS relationship using <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_957335314.gif" id="latex_383" apt_id="383"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_957335314.gif" apt_id="384" id="img_384" /><!--<?TeX ${\hat{g}_i}$?>--></latex>s in a multivariable additive hazard model described earlier. The model included all predicted genes. The genes with the significant <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1376491351.gif" id="latex_385" apt_id="385"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1376491351.gif" apt_id="386" id="img_386" /><!--<?TeX $\hat{g}$?>--></latex>-OS relationship (<i apt_id="387" id="i_387">p</i>-value &lt; 0.1) were considered as genes with causal effect on OS.</p>
</sect2><sect2 id="sect2_388" apt_id="388"><ti title="Heading 2" apt_id="389" id="ti_389">Replication analysis</ti>
<p t="fl" title="Paragraph No Indent" apt_id="390" id="p_390">For the replication of causal genes from the MR analysis, we performed two-sample MR study using 602 samples in the validation cohort (296 under bevacizumab treatment and 306 under cetuximab treatment) with genotype and clinical outcome and no RNA-seq data. We first compared the clinical characteristics and demography of patients in discovery and validation cohorts (Federico [<bibcit rid="647" title="bibcit" href="#" contenteditable="false" id="bibcit_391" sno="1" apt_id="391">1</bibcit>]) (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="392" id="url_392">Supplementary Table S1</url>) to ensure compatibility of the cohorts. We then predicted gene expression levels of the causal genes in the validation cohort using summary statistics of eQTLs from discovery cohort as:</p>
<eqn sub-type="" id="eqn_393" apt_id="393"><latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_2147019279.gif" apt_id="394" id="latex_394"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_2147019279.gif" apt_id="395" id="img_395" /><!--<?TeX \begin{equation*}\hat{g}_i^* = \ Q_i^*\ {\left( {Q_i^T{Q_i}} \right)^{ - 1}}Q_i^T{g_i},\end{equation*}?>--></latex></eqn>
<p t="cont" title="Paragraph Continue" apt_id="396" id="p_396">where <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_418691669.gif" id="latex_397" apt_id="397"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_418691669.gif" apt_id="398" id="img_398" /><!--<?TeX ${Q_i}$?>--></latex> is an <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_837847706.gif" id="latex_399" apt_id="399"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_837847706.gif" apt_id="400" id="img_400" /><!--<?TeX $n \times {p_i}$?>--></latex> matrix of eQTLs where <i apt_id="401" id="i_401">n</i> is the sample size in the discovery cohort (with eQTL) and <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1257003743.gif" id="latex_402" apt_id="402"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1257003743.gif" apt_id="403" id="img_403" /><!--<?TeX ${p_i}$?>--></latex> is the number of eQTLs selected as IVs for the <i apt_id="404" id="i_404">i</i>th gene (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_2027531671.gif" id="latex_405" apt_id="405"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_2027531671.gif" apt_id="406" id="img_406" /><!--<?TeX ${g_i}$?>--></latex>), and <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_299204061.gif" id="latex_407" apt_id="407"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_299204061.gif" apt_id="408" id="img_408" /><!--<?TeX $Q_i^*$?>--></latex> is a <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1069731989.gif" id="latex_409" apt_id="409"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1069731989.gif" apt_id="410" id="img_410" /><!--<?TeX ${n^*} \times {p_i}$?>--></latex> matrix where <latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_718360098.gif" id="latex_411" apt_id="411"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_718360098.gif" apt_id="412" id="img_412" /><!--<?TeX ${n^*}$?>--></latex> is the sample size in validation cohort. If the predicted expression levels (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_111932307.gif" id="latex_413" apt_id="413"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_111932307.gif" apt_id="414" id="img_414" /><!--<?TeX $\hat{g}_i^*$?>--></latex>) significantly affected OS via treatment-specific additive hazard model, we considered it a replication for the one-sample MR. This analysis has some similarities with transcriptome-wide association studies (TWAS). But the main difference is that, in the two-sample MR analysis, genetic variants as predictors satisfy MR assumptions, which might not be the case in TWAS.</p>
</sect2><sect2 id="sect2_415" apt_id="415"><ti title="Heading 2" apt_id="416" id="ti_416">Prognostic contribution</ti>
<p t="fl" title="Paragraph No Indent" apt_id="417" id="p_417">To assess the contribution of the identified treatment-specific biomarkers to the overall survival (OS) model, we performed a likelihood ratio test (LRT) comparing models with and without the biomarkers while adjusting for the covariates.</p>
</sect2></sect1><sect1 id="sect1_418" sec-type="results" apt_id="418"><ti title="Heading 1" apt_id="419" id="ti_419">Results</ti>
<p t="fl" title="Paragraph No Indent" apt_id="420" id="p_420">In our investigation of treatment-specific biomarkers predictive of CRC treatment response, we focused on cetuximab, and bevacizumab monoclonal antibodies used in the randomized phase III trial CALGB/SWOG 80405. The trial was designed to compare cetuximab, bevacizumab, or cetuximab + bevacizumab, each plus chemotherapy as first-line therapy in KRAS wild-type advanced or metastatic CRC. The discovery cohort encompassed 273 patients with pre-treatment tumor primary tissue RNA-seq and germline genotype data (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="421" id="url_421">Supplementary Figs S1</url>-<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="422" id="url_422">S2</url>). The validation cohort included 602 patients with germline genotype data (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="423" id="url_423">Supplementary Figs S1</url>-<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="424" id="url_424">S2</url>). In both cohorts, we had records of OS and conducted an MR technique, one- and two-sample MR to identify genes with causal effect on treatment-specific OS. In one-sample MR analysis, we assessed the causal effect of the genes associated with OS. We replicated the identified associations using TCGA data. To reproduce the causal impact of genes on OS, we predicted gene expression levels by germline genotype data in the validation cohort and eQTL summary statistics from the discovery cohort [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_425" sno="16" apt_id="425">16</bibcit>] and performed a two-sample MR analysis. In addition, we investigated the differential expression of the identified biomarkers between colorectal tumors vs. normal tissue using the GSE146889 dataset from the Gene Expression Omnibus database. We finally linked the findings to CMS to investigate the genetic basis underpinning CMS [<bibcit rid="665" title="bibcit" href="#" contenteditable="false" id="bibcit_426" sno="2" apt_id="426">2</bibcit>].</p>
<p t="i" title="Paragraph Indented" apt_id="427" id="p_427">The analyses reviewed above were adjusted for all RAS and BRAF V600E mutation statuses along with age and gender (Fig. <figcit rid="429" title="figcit" href="#" contenteditable="false" id="figcit_428" sno="1" apt_id="428">1</figcit>). Additionally, to enhance the precision of our findings, we accounted for the tumor microenvironment's influence by adjusting for enriched immune cell abundances in the RNA-seq data.</p>
<fig id="fig_429" prefix="Figure" suffix="." sno="1" type="arabic" sub-type="" apt_id="429"><ti title="Figure Caption" prefix="Figure" suffix="." sno="1" type="arabic" sub-type="" apt_id="430" id="ti_430">Study design and analytic workflow. The reported number of samples is after excluding patients with missing clinical outcomes or covariates. *: Published elsewhere [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_431" sno="16" apt_id="431">16</bibcit>] and involved n = 350 samples<query><button type="button" title="Copy Editor to Author-AU: Figures have been edited to conform to journal style. Please check all figures carefully. If any adjustments are needed, where possible please note these as instructions to the typesetter rather than providing a replacement figure." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="30" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">30</span></button></query>.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_f1.jpg" title="Figure" apt_id="434" id="img_434" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="435" id="button_435"><i class="fa-solid fa-pen-to-square" apt_id="436" id="i_436"></i></button></fig><sect2 id="sect2_437" apt_id="437"><ti title="Heading 2" apt_id="438" id="ti_438">The effect of genes on treatment-specific OS</ti>
<p t="fl" title="Paragraph No Indent" apt_id="439" id="p_439">To identify genes with causal effect on OS, we focused on 352 genes with eQTLs [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_440" sno="16" apt_id="440">16</bibcit>], since they are good candidates for MR analysis due to their higher likelihood of providing valid IVs. In the first step, we filtered these genes by investigating their association with OS using multivariable time-variant additive hazard regression model (Methods). Out of the 352 genes with eQTLs, 79 genes were associated with OS (<i apt_id="441" id="i_441">p</i>-value &lt; 0.1), including 47 under bevacizumab treatment and 32 under cetuximab (Fig. <figcit rid="447" title="figcit" href="#" contenteditable="false" id="figcit_442" sno="2" apt_id="442">2</figcit>A, <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="443" id="url_443">Supplementary Tables S2</url>-<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="444" id="url_444">S3</url>). We replicated the gene-OS associations using the TCGA data. The rate of replication was 78% and 75% for bevacizumab and cetuximab treatments, respectively (Fig. <figcit rid="447" title="figcit" href="#" contenteditable="false" id="figcit_445" sno="2" apt_id="445">2</figcit>B). Note that the replication rate is relatively high although the TCGA data is not a perfect replication set for the data in this study due to the higher censoring rate of the samples (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="446" id="url_446">Supplementary Fig. S8</url>).</p>
<fig id="fig_447" prefix="Figure" suffix="." sno="2" type="arabic" sub-type="" apt_id="447"><ti title="Figure Caption" prefix="Figure" suffix="." sno="2" type="arabic" sub-type="" apt_id="448" id="ti_448">Gene-OS relationships. <b apt_id="449" id="b_449">A.</b> The bar plot displays the z-scores for 79 genes significantly associated with OS (<i apt_id="450" id="i_450">p</i>-value &lt; 0.1), as determined using a treatment-specific additive multivariable hazard model (Method). Genes associated with OS in the bevacizumab arm are represented in cyan, while genes associated with OS in the cetuximab arm are shown in orange. <b apt_id="451" id="b_451">B.</b> The pie charts represent the percentage of replicated gene-OS association using univariate analysis of the TCGA data. The rate of replication is relatively high even though the censoring rate of TCGA-COAD data is higher than the data in this study. <b apt_id="452" id="b_452">C.</b> The Manhattan plot of the GWAS representing -<i apt_id="453" id="i_453">log10</i> (<i apt_id="454" id="i_454">p</i>-value) observed for genetic variants-OS associations. The GWAS threshold and the maximum -log(<i apt_id="455" id="i_455">p</i>-value) observed for the eQTL-OS associations are depicted on the plot. <b apt_id="456" id="b_456">D.</b> Genes causally associated with treatment-specific OS based on a one-sample MR technique (<i apt_id="457" id="i_457">p</i>-value ≤ 0.05). The <i apt_id="458" id="i_458">p</i>-values under both treatments are presented for comparison.</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_f2.jpg" title="Figure" apt_id="459" id="img_459" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="460" id="button_460"><i class="fa-solid fa-pen-to-square" apt_id="461" id="i_461"></i></button></fig>
<p t="i" title="Paragraph Indented" apt_id="462" id="p_462">The association between genes and OS was conducted using multivariable time-variant additive hazard regression model which relaxes the assumption of the time-invariant effect of the genes on OS and allows for estimating the causal effects [<bibcit rid="936" title="bibcit" href="#" contenteditable="false" id="bibcit_463" sno="17" apt_id="463">17</bibcit>] in the second step. Therefore, focusing on 79 genes associated with OS in the second step, we investigated the causal associations using one-sample MR technique with treatment-specific OS as outcomes, gene expressions as explanatory variables (exposures), and eQTLs as instrumental variables (IVs). To evaluate the validity of eQTLs as IVs, we assessed the lack of pleiotropic action by performing a genome-wide association study (GWAS) to find the association of the eQTLs with OS. The eQTLs did not show any significant association with OS at a level 1 × 10<sup apt_id="464" id="sup_464">−4</sup>, which is much larger than the GWAS threshold (5 × 10<sup apt_id="465" id="sup_465">−8</sup>) (Fig. <figcit rid="447" title="figcit" href="#" contenteditable="false" id="figcit_466" sno="2" apt_id="466">2</figcit>C, <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="467" id="url_467">Supplementary Fig. S9</url>). Using the eQTLs as valid IVs, we predicted the expression levels of genes and estimated their causal effect on OS (Methods). We identified 5 genes with causal effect on OS (<i apt_id="468" id="i_468">p</i>-value &lt; 0.05), including <i apt_id="469" id="i_469">OSBPL1A</i>, <i apt_id="470" id="i_470">SEMA6C</i>, and <i apt_id="471" id="i_471">SCD5</i> under bevacizumab treatment and <i apt_id="472" id="i_472">WDR62</i> and <i apt_id="473" id="i_473">TCEA3</i> under cetuximab (Fig. <figcit rid="447" title="figcit" href="#" contenteditable="false" id="figcit_474" sno="2" apt_id="474">2</figcit>D).</p>
</sect2><sect2 id="sect2_475" apt_id="475"><ti title="Heading 2" apt_id="476" id="ti_476">Replication of the causal genes</ti>
<p t="fl" title="Paragraph No Indent" apt_id="477" id="p_477">We reproduced the findings of one-sample MR analysis in the discovery cohort by performing a two-sample MR in the validation cohort. Using the eQTL summary statistics in CALGB-80405 [<bibcit rid="918" title="bibcit" href="#" contenteditable="false" id="bibcit_478" sno="16" apt_id="478">16</bibcit>] and the genotyping data in the validation cohort, we predicted expression levels in the validation cohort. We then estimated the effect of predicted genes on treatment-specific OS which represents the causal effect of the corresponding genes on OS (Methods). The <i apt_id="479" id="i_479">p</i>-values of significant genes-OS causal associations followed the same trend in the discovery and validation cohorts for bevacizumab vs. cetuximab, except <i apt_id="480" id="i_480">OSBPL1A</i>, (Fig. <figcit rid="485" title="figcit" href="#" contenteditable="false" id="figcit_481" sno="3" apt_id="481">3</figcit>A and B). In addition, among the significant genes in the discovery cohort, all showed a slight increase in <i apt_id="482" id="i_482">p</i>-value in the validation cohort, except for <i apt_id="483" id="i_483">TCEA3</i>. Additional details are provided in <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="484" id="url_484">Supplementary Table S4</url>.</p>
<fig id="fig_485" prefix="Figure" suffix="." sno="3" type="arabic" sub-type="" apt_id="485"><ti title="Figure Caption" prefix="Figure" suffix="." sno="3" type="arabic" sub-type="" apt_id="486" id="ti_486">Replication of causal genes. <b apt_id="487" id="b_487">A.</b> Replication of causal effect of genes on treatment-specific OS in a validation cohort. The cyan bars represent <i apt_id="488" id="i_488">p</i>-values calculated in the discovery cohort using one-sample MR analysis for each treatment. The navy bars represent <i apt_id="489" id="i_489">p</i>-values calculated in the validation cohort using a two-sample MR study. The dashed line shows the <i apt_id="490" id="i_490">p</i>-value threshold level for significance. <b apt_id="491" id="b_491">B.</b> Illustrates the subtype-specific distribution of gene expression and their enrichment. The red dashed line represents the median expression level observed across all samples. <b apt_id="492" id="b_492">C.</b> The enrichment of gene expressions causally associated with overall survival in each subtype is determined based on the high percentage of patients with beneficial or non-beneficial gene expression within that specific subtype (&gt;70%).</ti><img src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_f3.jpg" title="Figure" apt_id="493" id="img_493" /><button class="btn_inline_img noneditable btn btn-info btn-sm" onclick="AptEditorImgManager.initImageManagerButton($(e.target).prev()[0]);" apt_id="494" id="button_494"><i class="fa-solid fa-pen-to-square" apt_id="495" id="i_495"></i></button></fig>
<p t="i" title="Paragraph Indented" apt_id="496" id="p_496">Furthermore, this analysis replicated the significant causal effects of <i apt_id="497" id="i_497">WDR62</i> and <i apt_id="498" id="i_498">SCD5</i>, which were identified in the discovery cohort. The negative causal effect of <i apt_id="499" id="i_499">WDR62</i> on OS under cetuximab treatment (<i apt_id="500" id="i_500">p</i>-value: 0.008) compared to bevacizumab (<i apt_id="501" id="i_501">p</i>-value: 0.16) was replicated. <i apt_id="502" id="i_502">WDR62</i> is a Protein Coding gene that is implicated in the carcinogenesis of various cancers including CRC. <i apt_id="503" id="i_503">WDR62</i> promotes tumor growth, resistance to oxaliplatin, enhance DNA repair in CRC cells (Juanjuan [<bibcit rid="954" title="bibcit" href="#" contenteditable="false" id="bibcit_504" sno="18" apt_id="504">18</bibcit>]).</p>
<p t="i" title="Paragraph Indented" apt_id="505" id="p_505">The positive causal effect of <i apt_id="506" id="i_506">SCD5</i> was also replicated, indicating its impact on OS under bevacizumab (<i apt_id="507" id="i_507">p</i>-value: 0.075) compared to cetuximab (<i apt_id="508" id="i_508">p</i>-value: 0.841). SCD5 is the stearoyl-CoA desaturating enzymes that convert of saturated fatty acids to monounsaturated fatty acids. Due to its effects on fatty acid metabolism, it could potentially reduce tumor aggressiveness and promote immune activation as reported for breast cancer [<bibcit rid="971" title="bibcit" href="#" contenteditable="false" id="bibcit_509" sno="19" apt_id="509">19</bibcit>].</p>
<p t="i" title="Paragraph Indented" apt_id="510" id="p_510">In addition, we investigated whether genes causally associated with OS show differential expression between normal and tumor tissues. To assess this, we utilized GSE146889 data from the Gene Expression Omnibus database [<bibcit rid="989" title="bibcit" href="#" contenteditable="false" id="bibcit_511" sno="20" apt_id="511">20</bibcit>] as an external cohort, focusing on 24 paired samples from normal and tumor tissue of CRC patients (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="512" id="url_512">Supplementary Table S5</url>). Differential expression analysis revealed significant dysregulation of <i apt_id="513" id="i_513">OSBPL1A</i> and <i apt_id="514" id="i_514">WDR62</i> (FC: 0.61, p-value: 0.001; FC: 4.56, p-value: &lt; 0.0001). The expression distribution of the genes with causal impact on OS in the external replicated cohort GSE146889 is shown in <url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="515" id="url_515">Supplementary Fig. S10</url>. Note that this analysis was not adjusted for covariates, as we did not have access to them, unlike the main analysis.</p>
</sect2><sect2 id="sect2_516" apt_id="516"><ti title="Heading 2" apt_id="517" id="ti_517">Prognostic contribution of the replicated treatment-specific biomarkers</ti>
<p t="fl" title="Paragraph No Indent" apt_id="518" id="p_518">We further assessed the contribution of the replicated genes (<i apt_id="519" id="i_519">WDR62</i>, <i apt_id="520" id="i_520">SCD5</i>) to the prognostic models for treatment-specific OS. A likelihood ratio test (LRT) was performed to compare models with and without <i apt_id="521" id="i_521">SCD5</i> for patients treated with bevacizumab, and with and without <i apt_id="522" id="i_522">WDR62</i> for those treated with cetuximab. All models were adjusted for covariates, including gender, age, BRAF V600E mutations and all RAS mutation status, batch effects, enriched cell type abundance. In both treatment groups, incorporating the respective biomarkers significantly improved the prognostic models (bevacizumab: χ²(1) = 5.99, <i apt_id="523" id="i_523">p</i> = 0.014; cetuximab: χ²(1) = 3.4, <i apt_id="524" id="i_524">p</i> = 0.065), with a more pronounced enhancement observed in the bevacizumab arm.</p>
<p t="i" title="Paragraph Indented" apt_id="525" id="p_525">To support the visualization of survival outcomes, we dichotomized the expression level of replicated genes into “high” and “low” groups using the median expressions as the cutoff. Kaplan–Meier estimators were then used to estimate the survival functions (<url title="URL" type="uri" href="https://academic.oup.com/nargab/article-lookup/doi/10.1093/nargab/lqaf053#supplementary-data" apt_id="526" id="url_526">Supplementary Fig. S11</url>). It is important to note that dichotomizing continuous variables for KM analysis can obscure more nuanced associations and may not fully capture the continuous relationship between gene expression signatures and OS.</p>
</sect2><sect2 id="sect2_527" apt_id="527"><ti title="Heading 2" apt_id="528" id="ti_528">Enrichment analysis for colorectal cancer subtypes</ti>
<p t="fl" title="Paragraph No Indent" apt_id="529" id="p_529">We investigated if the causal genes are enriched in CMSs of colorectal cancer: CMS1 (MSI Immune)- Tumors with high microsatellite instability (MSI-H) and strong immune activation; CMS2 (Canonical)- Tumors with features of traditional CRC, characterized by WNT and MYC signaling activation; CMS3 (Metabolic)- Tumors with metabolic dysregulation and KRAS mutations; CMS4 (Mesenchymal)- Tumors with prominent stromal infiltration, inflammation, and angiogenesis [<bibcit rid="665" title="bibcit" href="#" contenteditable="false" id="bibcit_530" sno="2" apt_id="530">2</bibcit>]. We dichotomized the expression levels of the causal genes into two categories, “<i apt_id="531" id="i_531">beneficial</i>” and “non-<i apt_id="532" id="i_532">beneficial</i>,” based on their association with OS. This categorization was determined by the median expression level across all samples in our study. For genes where higher expression elongated OS, patients with expression levels above the median were classified as “beneficial,” and those below the median as “non-beneficial.” For genes where higher expression shortened OS, the classification was reversed, with patients having expression levels below the median classified as “beneficial” and those above the median as “non-beneficial.” We then calculated the proportion of patients with “beneficial” and “non-beneficial” expression levels within each subtype. We considered a threshold of 70%, and if over 70% of patients within a specific subtype showed either “beneficial” or “non-beneficial” gene expression, the subtype was considered enriched for the expression of the gene. Non-beneficial expressions of <i apt_id="533" id="i_533">OSBPL1A</i> and <i apt_id="534" id="i_534">WDR62</i> were enriched in CMS1 (rate 76% and 81%, respectively), whereas its beneficial expression levels were enriched in CMS2 (rate 72%). The CMS3 subtype exhibits an enrichment of non-beneficial levels of <i apt_id="535" id="i_535">TCEA3</i> (Rate: 83%), and the CMS4 subtype exhibits an enrichment of beneficial expression levels of <i apt_id="536" id="i_536">SEMA6C</i>, <i apt_id="537" id="i_537">SCD5</i>, and <i apt_id="538" id="i_538">WDR62</i> (Rate: 75%, 73%, 79%, respectively), (Fig. <figcit rid="485" title="figcit" href="#" contenteditable="false" id="figcit_539" sno="3" apt_id="539">3</figcit>C). The distribution of gene expressions specific to each subtype indicated an enrichment of gene expressions causally associated with overall survival in a specific subtype (Fig. <figcit rid="485" title="figcit" href="#" contenteditable="false" id="figcit_540" sno="3" apt_id="540">3</figcit>B).</p>
<p t="i" title="Paragraph Indented" apt_id="541" id="p_541">We evaluated the contribution of the identified novel biomarkers to the prognostic models for treatment-specific OS in the presence of CMS classification using a likelihood ratio test (LRT). In the bevacizumab arm, we observed a significant improvement in model fit (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_531088344.gif" id="latex_542" apt_id="542"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_531088344.gif" apt_id="543" id="img_543" /><!--<?TeX $\chi _{( 3 )}^2$?>--></latex> = 9.68, <i apt_id="544" id="i_544">p</i>-value = 0.021) upon inclusion of the identified novel biomarkers (<i apt_id="545" id="i_545">OSBPL1A, SEMA6C, and SCD5</i>). For cetuximab arm, we observed a modest improvement in model fit (<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_950244381.gif" id="latex_546" apt_id="546"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_950244381.gif" apt_id="547" id="img_547" /><!--<?TeX $\chi _{( 2 )}^2$?>--></latex> = 4.2, <i apt_id="548" id="i_548">p</i> = 0.122) upon inclusion of the identified novel biomarkers (<i apt_id="549" id="i_549">TCEA3</i> and <i apt_id="550" id="i_550">WDR62</i>), though it did not reach statistical significance.</p>
</sect2></sect1><sect1 id="sect1_551" sec-type="discussion" apt_id="551"><ti title="Heading 1" apt_id="552" id="ti_552">Discussion</ti>
<p t="fl" title="Paragraph No Indent" apt_id="553" id="p_553">Here, we integrated germline genotype and RNA-seq data from a randomized phase III trial and assessed the causal effect of gene expressions on OS of patients treated with either cetuximab or bevacizumab monoclonal antibodies. We identified 47 genes associated with OS of patients treated with bevacizumab and 32 genes in cetuximab, where three genes <i apt_id="554" id="i_554">OSBPL1A</i>, <i apt_id="555" id="i_555">SCD5</i>, and <i apt_id="556" id="i_556">SEMA6C</i> showed causal effect on OS in bevacizumab arm and two genes <i apt_id="557" id="i_557">TCEA3</i> and <i apt_id="558" id="i_558">WDR62</i> in cetuximab respectively. Replicating these results using external cohort represented differential expression of <i apt_id="559" id="i_559">OSBPL1A</i>, <i apt_id="560" id="i_560">SEMA6C, TCEA3,</i> and <i apt_id="561" id="i_561">WDR62</i>. We also replicated the causal effect of <i apt_id="562" id="i_562">WDR62</i> and <i apt_id="563" id="i_563">SCD5</i> on OS using a validation cohort with 602 additional samples.</p>
<p t="i" title="Paragraph Indented" apt_id="564" id="p_564"><i apt_id="565" id="i_565">TCEA3</i> (Transcription Elongation Factor A3) is a protein-coding gene that is involved in the regulation of transcription, particularly in the elongation phase of transcription. Our study showed that the overexpression of <i apt_id="566" id="i_566">TCEA3</i> reduces the OS of patients treated with cetuximab. Additionally, more than 80% of patients with the CMS3 subtype exhibited high expression of <i apt_id="567" id="i_567">TCEA3</i>. In consistence with this finding here, the inhibition of <i apt_id="568" id="i_568">TCEA3</i> is suggested as an effective agent to enhance various chemotherapeutics-induced pyroptosis [<bibcit rid="1007" title="bibcit" href="#" contenteditable="false" id="bibcit_569" sno="21" apt_id="569">21</bibcit>].</p>
<p t="i" title="Paragraph Indented" apt_id="570" id="p_570"><i apt_id="571" id="i_571">OSBPL1A</i> (Oxysterol-Binding Protein-Like 1A) is a gene that encodes a protein involved in the transport and regulation of lipids, specifically oxysterols. Oxysterols are oxidized derivatives of cholesterol and play roles in various cellular processes, including cholesterol homeostasis and lipid signaling which can affect the development and progression of various cancers, such as CRC. We observed negative impact of high expression of this gene on the OS of patients treated with bevacizumab, which was enriched among patients with CMS1 subtype.</p>
<p t="i" title="Paragraph Indented" apt_id="572" id="p_572">Our study revealed that the upregulation of <i apt_id="573" id="i_573">SCD5</i> (Stearoyl-CoA Desaturase 5) potentially elongates OS in patients treated with bevacizumab, which is a VEGF inhibitor. <i apt_id="574" id="i_574">SCD5</i> is required for lipid synthesis, a key regulator of energy metabolism. Dysregulation of <i apt_id="575" id="i_575">SCD5</i> may play a role in dyslipidemia, characterized by abnormal lipid levels in the blood. Furthermore, dyslipidemia has been associated with CRC and tumor progression [<bibcit rid="1025" title="bibcit" href="#" contenteditable="false" id="bibcit_576" sno="22" apt_id="576">22</bibcit>]. Moreover, the risk of dyslipidemia with the use of VEGF/VEGFR inhibitors has been observed [<bibcit rid="1042" title="bibcit" href="#" contenteditable="false" id="bibcit_577" sno="23" apt_id="577">23</bibcit>]. Therefore, understanding the interplay between <i apt_id="578" id="i_578">SCD5</i>, dyslipidemia, and VEGF inhibition could yield valuable insights into CRC pathogenesis and therapeutic strategies.</p>
<p t="i" title="Paragraph Indented" apt_id="579" id="p_579">Furthermore, our study showed that the overexpression of <i apt_id="580" id="i_580">WDR62</i> (WD repeat domain 62) shortened the OS of patients treated with cetuximab and may contribute to cetuximab-resistant CRC. WDR62 is a scaffold protein involved in several important cellular processes, such as forming of the structure of the cell nucleus, regulation of gene expression, and ensuring proper division of cells during cell division. <i apt_id="581" id="i_581">WDR62</i> coordinates TNFα receptor signaling pathway to the JNK activation [<bibcit rid="1060" title="bibcit" href="#" contenteditable="false" id="bibcit_582" sno="24" apt_id="582">24</bibcit>]. In addition, there is a complex interaction between TNF<latex src="https://pxeqa.aptaracorp.com/ED6010/home/lqaf053_peqn_1720772309.gif" id="latex_583" apt_id="583"><img class="img" src="https://pxeqa.aptaracorp.com/pxestore/assets/pxeoup6qa/NARGAB/lqaf053//images/lqaf053_peqn_1720772309.gif" apt_id="584" id="img_584" /><!--<?TeX $\alpha $?>--></latex> and EGFR, which is the targeted pathway of cetuximab [<bibcit rid="1077" title="bibcit" href="#" contenteditable="false" id="bibcit_585" sno="25" apt_id="585">25</bibcit>]. WDR62 also contributes to multidrug resistance of gastric cancer through activation of MAPK signaling [<bibcit rid="954" title="bibcit" href="#" contenteditable="false" id="bibcit_586" sno="18" apt_id="586">18</bibcit>]. In our study, overexpression of <i apt_id="587" id="i_587">WDR62</i> is enriched in CMS1 whereas its under expression is enriched in CMS4. Therefore, <i apt_id="588" id="i_588">WDR62</i> may be instrumental in understanding interactions between JNK signaling and specific CRC subtypes, potentially contributing to the development of more personalized and effective treatment strategies.</p>
<p t="i" title="Paragraph Indented" apt_id="589" id="p_589">Collectively, our study underscores the utility of incorporating genotype data into gene-OS investigations to discover novel biomarkers with causal associations with OS in observational studies and to shed light on mechanisms underlying response to specific treatments.</p>
</sect1><sect1 sec-type="ack" apt_id="590" id="sect1_590"><ti title="Acknowledgement Heading" apt_id="591" id="ti_591">Acknowledgements</ti>
<p t="fl" title="Paragraph No Indent" apt_id="592" id="p_592">Research reported in this publication was supported by the NCI of the NIH under Award Numbers U10CA180821, U10CA180882, and U24CA196171 (to the Alliance for Clinical Trials in Oncology). Also supported in part by funds from Bristol-Myers Squibb, Genentech, Pfizer, and Sanofi<query><button type="button" title="Copy Editor to Author-AU: Please ensure all 'conflicts of interest' (or 'disclosures') have been included for you and your co-authors, and that this section is correct. Edit the text directly if changes are required." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="31" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">31</span></button></query><query><button type="button" title="Copy Editor to Author-AU: Please check that funding is recorded in a separate funding section, if applicable. Use the full official names of any funding bodies and include any grant numbers. Insert any changes to the funding section directly in the text." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="32" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">32</span></button></query>.</p>
</sect1><sect1 id="sect1_597" sec-type="declaration-of-interests" apt_id="597"><ti title="Heading 1" apt_id="598" id="ti_598">Competing interests</ti>
<p t="fl" title="Paragraph No Indent" apt_id="599" id="p_599">The authors declare no competing interests.</p>
</sect1><sect1 id="sect1_600" sec-type="author-contrib" apt_id="600"><ti title="Heading 1" apt_id="601" id="ti_601">Contributions</ti>
<p t="fl" title="Paragraph No Indent" apt_id="602" id="p_602">(AY* here represents the first and corresponding author)</p>
</sect1><sect1 id="sect1_603" sec-type="supplementary-material" apt_id="603"><ti title="Heading 1" apt_id="604" id="ti_604">Supplementary material</ti>
<p t="fl" title="Paragraph No Indent" exinfo="spinfo" apt_id="605" id="p_605">Supplementary Data are available at NARGAB Online.</p>
</sect1><sect1 id="sect1_606" sec-type="conceptual-method" apt_id="606"><ti title="Heading 1" apt_id="607" id="ti_607"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="608" id="p_608">Conceptualization and methodology: AY*</p>
</sect1><sect1 id="sect1_609" sec-type="formal-analysis" apt_id="609"><ti title="Heading 1" apt_id="610" id="ti_610"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="611" id="p_611">Formal analysis: AY*, AY, RMG</p>
</sect1><sect1 id="sect1_612" sec-type="visual-replication" apt_id="612"><ti title="Heading 1" apt_id="613" id="ti_613"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="614" id="p_614">Visualization and replication analysis: AY*, RMG, AY, ES, RH, AS</p>
</sect1><sect1 id="sect1_615" sec-type="resources" apt_id="615"><ti title="Heading 1" apt_id="616" id="ti_616"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="617" id="p_617">Resources: FI, MMB, HL, AV</p>
</sect1><sect1 id="sect1_618" sec-type="data-curation" apt_id="618"><ti title="Heading 1" apt_id="619" id="ti_619"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="620" id="p_620">Data curation: AY*, RMG</p>
</sect1><sect1 id="sect1_621" sec-type="original-draft" apt_id="621"><ti title="Heading 1" apt_id="622" id="ti_622"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="623" id="p_623">Writing Original Draft: AY*</p>
</sect1><sect1 id="sect1_624" sec-type="review-edit" apt_id="624"><ti title="Heading 1" apt_id="625" id="ti_625"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="626" id="p_626">Review and Edits: AY*, AY, RGM, CMP, SK, GP, ABN, MMB, HL, JAL, FI</p>
</sect1><sect1 id="sect1_627" sec-type="superviosion" apt_id="627"><ti title="Heading 1" apt_id="628" id="ti_628"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="629" id="p_629">Supervision: AY*</p>
</sect1><sect1 id="sect1_630" sec-type="funding-acquisition" apt_id="630"><ti title="Heading 1" apt_id="631" id="ti_631"></ti>
<p t="fl" title="Paragraph No Indent" apt_id="632" id="p_632">Funding Acquisition: FI, MMB<query><button type="button" title="Copy Editor to Author-AU: We have received the following files for publication as supplementary material. [Filename] These will be published in the format provided, without edits. If any files need to be removed from this list, specify by responding to this query, stating the filename. If any files need to be added, upload them directly or email them with your proof corrections. If any files need to be updated, upload them directly or email them, without altering the filename. We will seek editor approval for any changes to supplementary material, which may delay publication of your article." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="33" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">33</span></button></query></p>
</sect1><sect1 id="sect1_635" sec-type="ConflictofInterest" apt_id="635"><ti title="Heading 1" apt_id="636" id="ti_636">Conflict of interest statement</ti>
<p t="fl" title="Paragraph No Indent" apt_id="637" id="p_637">None declared</p>
</sect1><sect1 id="sect1_638" sec-type="data-availability" apt_id="638"><ti title="Heading 1" apt_id="639" id="ti_639">Data availability</ti>
<p t="fl" title="Paragraph No Indent" apt_id="640" id="p_640">The gene expression data used in this study are publicly available in Gene Expression Omnibus at GSE196576. The genotype data can be accessed upon approval from the National Institutes of Health (NIH). For the external cohorts, the TCGA data was obtained using the TCGAbiolinks R package and The Human Protein Atlas, and the second external cohort was downloaded from GEO (GSE146889).</p>
<p t="i" title="Paragraph Indented" apt_id="641" id="p_641">The code is accessible via GitHub repository at <url title="URL" type="uri" href="https://github.com/AkramYazdani/MR/blob/main/R_Script.txt" apt_id="642" id="url_642">https://github.com/AkramYazdani/MR/blob/main/R_Script.txt</url>, and Harvard Dataverse, <url title="URL" type="uri" href="https://doi.org/10.7910/DVN/IQHEGF" apt_id="643" id="url_643">https://doi.org/10.7910/DVN/IQHEGF</url>.</p>
</sect1></bdy><bm apt_id="644" id="bm_644"><ref type="arabic" sno="1" suffix="." id="ref_645" apt_id="645"><ti title="Bibliography Heading" apt_id="646" id="ti_646">References</ti><bib type="arabic" id="bib_647" sno="1" suffix="." apt_id="647"><jcit apt_id="648" id="jcit_648"><au apt_id="649" id="au_649"><s title="Surname" apt_id="650" id="s_650">Innocenti</s><f title="First name" apt_id="651" id="f_651">F</f></au>, <au apt_id="652" id="au_652"><s title="Surname" apt_id="653" id="s_653">Yazdani</s><f title="First name" apt_id="654" id="f_654">A</f></au>, <au apt_id="655" id="au_655"><s title="Surname" apt_id="656" id="s_656">Rashid</s><f title="First name" apt_id="657" id="f_657">N.</f></au>, <etal title="etal" apt_id="658" id="etal_658">et al.</etal> <at title="Article Title" apt_id="659" id="at_659">Tumor immunogenomic features determine outcomes in patients with metastatic colorectal cancer treated with standard-of-care combinations of Bevacizumab and Cetuximab</at>. <pt title="Periodical Title" apt_id="660" id="pt_660">Clin Cancer Res</pt> <yr title="Year" apt_id="661" id="yr_661">2022</yr>;<v title="Volume" apt_id="662" id="v_662">28</v>:<pages title="Pages" apt_id="663" id="pages_663">1690–700</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/1078-0432.CCR-21-3202" apt_id="664" id="url_664">https://doi.org/10.1158/1078-0432.CCR-21-3202</url> </jcit></bib><bib type="arabic" id="bib_665" sno="2" suffix="." apt_id="665"><jcit apt_id="666" id="jcit_666"><au apt_id="667" id="au_667"><s title="Surname" apt_id="668" id="s_668">Guinney</s><f title="First name" apt_id="669" id="f_669">J</f></au>, <au apt_id="670" id="au_670"><s title="Surname" apt_id="671" id="s_671">Dienstmann</s><f title="First name" apt_id="672" id="f_672">R</f></au>, <au apt_id="673" id="au_673"><s title="Surname" apt_id="674" id="s_674">Wang</s><f title="First name" apt_id="675" id="f_675">X.</f></au>, <etal title="etal" apt_id="676" id="etal_676">et al.</etal> <at title="Article Title" apt_id="677" id="at_677">The consensus molecular subtypes of colorectal cancer</at>. <pt title="Periodical Title" apt_id="678" id="pt_678">Nat Med</pt> <yr title="Year" apt_id="679" id="yr_679">2015</yr>;<v title="Volume" apt_id="680" id="v_680">21</v>:<pages title="Pages" apt_id="681" id="pages_681">1350–6</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nm.3967" apt_id="682" id="url_682">https://doi.org/10.1038/nm.3967</url> </jcit></bib><bib type="arabic" id="bib_683" sno="3" suffix="." apt_id="683"><othcit exinfo="journal" apt_id="684" id="othcit_684"><au apt_id="685" id="au_685"><s title="Surname" apt_id="686" id="s_686">Lenz</s><f title="First name" apt_id="687" id="f_687">HJ</f></au>, <au apt_id="688" id="au_688"><s title="Surname" apt_id="689" id="s_689">Ou</s><f title="First name" apt_id="690" id="f_690">FS</f></au>, <au apt_id="691" id="au_691"><s title="Surname" apt_id="692" id="s_692">Venook</s><f title="First name" apt_id="693" id="f_693">AP.</f></au>, <etal title="etal" apt_id="694" id="etal_694">et al.</etal> <at title="Article Title" apt_id="695" id="at_695">Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405 (Alliance)</at>. <i apt_id="696" id="i_696">In</i> <pt title="Periodical Title" apt_id="697" id="pt_697">JCO</pt> <yr title="Year" apt_id="698" id="yr_698">2019</yr>;<v title="Volume" apt_id="699" id="v_699">37</v>:<pages title="Pages" apt_id="700" id="pages_700">1876–85</pages>. <url title="URL" type="uri" href="https://doi.org/10.1200/JCO.18.02258" apt_id="701" id="url_701">https://doi.org/10.1200/JCO.18.02258</url> </othcit></bib><bib type="arabic" id="bib_702" sno="4" suffix="." apt_id="702"><jcit apt_id="703" id="jcit_703"><au apt_id="704" id="au_704"><s title="Surname" apt_id="705" id="s_705">Bhukdee</s><f title="First name" apt_id="706" id="f_706">D</f></au>, <au apt_id="707" id="au_707"><s title="Surname" apt_id="708" id="s_708">Nuwongsri</s><f title="First name" apt_id="709" id="f_709">P</f></au>, <au apt_id="710" id="au_710"><s title="Surname" apt_id="711" id="s_711">Israsena</s><f title="First name" apt_id="712" id="f_712">N.</f></au>, <etal title="etal" apt_id="713" id="etal_713">et al.</etal> <at title="Article Title" apt_id="714" id="at_714">Improved delineation of colorectal cancer molecular subtypes and functional profiles with a 62-gene panel</at>. <pt title="Periodical Title" apt_id="715" id="pt_715">Mol Cancer Res</pt> <yr title="Year" apt_id="716" id="yr_716">2023</yr>;<v title="Volume" apt_id="717" id="v_717">21</v>:<pages title="Pages" apt_id="718" id="pages_718">240–52</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/1541-7786.MCR-22-0476" apt_id="719" id="url_719">https://doi.org/10.1158/1541-7786.MCR-22-0476</url> </jcit></bib><bib type="arabic" id="bib_720" sno="5" suffix="." apt_id="720"><jcit apt_id="721" id="jcit_721"><au apt_id="722" id="au_722"><s title="Surname" apt_id="723" id="s_723">Hintzen</s><f title="First name" apt_id="724" id="f_724">G</f></au>, <au apt_id="725" id="au_725"><s title="Surname" apt_id="726" id="s_726">Dulat</s><f title="First name" apt_id="727" id="f_727">HJ</f></au>, <au apt_id="728" id="au_728"><s title="Surname" apt_id="729" id="s_729">Rajkovic</s><f title="First name" apt_id="730" id="f_730">E.</f></au>, <at title="Article Title" apt_id="731" id="at_731">Engaging innate immunity for targeting the epidermal growth factor receptor: therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling</at>. <pt title="Periodical Title" apt_id="732" id="pt_732">Front. Oncol.</pt> <yr title="Year" apt_id="733" id="yr_733">2022</yr>;<v title="Volume" apt_id="734" id="v_734">12</v>:<pages title="Pages" apt_id="735" id="pages_735">892212</pages>. <url title="URL" type="uri" href="https://doi.org/10.3389/fonc.2022.892212" apt_id="736" id="url_736">https://doi.org/10.3389/fonc.2022.892212</url> </jcit></bib><bib type="arabic" id="bib_737" sno="6" suffix="." apt_id="737"><othcit exinfo="journal" apt_id="738" id="othcit_738"><au apt_id="739" id="au_739"><s title="Surname" apt_id="740" id="s_740">Venook</s><f title="First name" apt_id="741" id="f_741">AP</f></au>, <au apt_id="742" id="au_742"><s title="Surname" apt_id="743" id="s_743">Niedzwiecki</s><f title="First name" apt_id="744" id="f_744">D</f></au>, <au apt_id="745" id="au_745"><s title="Surname" apt_id="746" id="s_746">Lenz</s><f title="First name" apt_id="747" id="f_747">H-J.</f></au>, <etal title="etal" apt_id="748" id="etal_748">et al.</etal> <at title="Article Title" apt_id="749" id="at_749">Effect of first-line chemotherapy combined with Cetuximab or Bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer A randomized clinical trial supplemental content</at>. <yr title="Year" apt_id="750" id="yr_750">2017</yr>;<v title="Volume" apt_id="751" id="v_751">317</v>:<pages title="Pages" apt_id="752" id="pages_752">2392–401</pages>.<query><button type="button" title="Copy Editor to Author-AU: JournalTitle is missing in this reference [25]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="34" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">34</span></button></query></othcit></bib><bib type="arabic" id="bib_755" sno="7" suffix="." apt_id="755"><jcit apt_id="756" id="jcit_756"><au apt_id="757" id="au_757"><s title="Surname" apt_id="758" id="s_758">Innocenti</s><f title="First name" apt_id="759" id="f_759">F</f></au>, <au apt_id="760" id="au_760"><s title="Surname" apt_id="761" id="s_761">Sibley</s><f title="First name" apt_id="762" id="f_762">AB</f></au>, <au apt_id="763" id="au_763"><s title="Surname" apt_id="764" id="s_764">Patil</s><f title="First name" apt_id="765" id="f_765">SA.</f></au>, <etal title="etal" apt_id="766" id="etal_766">et al.</etal> <at title="Article Title" apt_id="767" id="at_767">Genomic analysis of germline variation associated with survival of patients with colorectal cancer treated with Chemotherapy plus biologics in CALGB/SWOG 80405 (Alliance)</at>. <pt title="Periodical Title" apt_id="768" id="pt_768">Clin Cancer Res</pt> <yr title="Year" apt_id="769" id="yr_769">2021</yr>;<v title="Volume" apt_id="770" id="v_770">27</v>:<pages title="Pages" apt_id="771" id="pages_771">267–75</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/1078-0432.CCR-20-2021" apt_id="772" id="url_772">https://doi.org/10.1158/1078-0432.CCR-20-2021</url> </jcit></bib><bib type="arabic" id="bib_773" sno="8" suffix="." apt_id="773"><jcit apt_id="774" id="jcit_774"><au apt_id="775" id="au_775"><s title="Surname" apt_id="776" id="s_776">Kalari</s><f title="First name" apt_id="777" id="f_777">KR</f></au>, <au apt_id="778" id="au_778"><s title="Surname" apt_id="779" id="s_779">Nair</s><f title="First name" apt_id="780" id="f_780">AA</f></au>, <au apt_id="781" id="au_781"><s title="Surname" apt_id="782" id="s_782">Bhavsar</s><f title="First name" apt_id="783" id="f_783">JD.</f></au>, <etal title="etal" apt_id="784" id="etal_784">et al.</etal> <at title="Article Title" apt_id="785" id="at_785">MAP-RSeq: mayo Analysis pipeline for RNA sequencing</at>. <pt title="Periodical Title" apt_id="786" id="pt_786">BMC Bioinf</pt> <yr title="Year" apt_id="787" id="yr_787">2014</yr>;<v title="Volume" apt_id="788" id="v_788">15</v>:<pages title="Pages" apt_id="789" id="pages_789">1–11</pages>. <url title="URL" type="uri" href="https://doi.org/10.1186/1471-2105-15-224" apt_id="790" id="url_790">https://doi.org/10.1186/1471-2105-15-224</url> </jcit></bib><bib type="arabic" id="bib_791" sno="9" suffix="." apt_id="791"><jcit apt_id="792" id="jcit_792"><au apt_id="793" id="au_793"><s title="Surname" apt_id="794" id="s_794">Yuan</s><f title="First name" apt_id="795" id="f_795">C</f></au>, <au apt_id="796" id="au_796"><s title="Surname" apt_id="797" id="s_797">Sato</s><f title="First name" apt_id="798" id="f_798">K</f></au>, <au apt_id="799" id="au_799"><s title="Surname" apt_id="800" id="s_800">Hollis</s><f title="First name" apt_id="801" id="f_801">BW.</f></au>, <etal title="etal" apt_id="802" id="etal_802">et al.</etal> <at title="Article Title" apt_id="803" id="at_803">Plasma 25-hydroxyvitamin D levels and survival in patients with advanced or metastatic colorectal cancer: findings from CALGB/SWOG 80405 (Alliance)</at>. <pt title="Periodical Title" apt_id="804" id="pt_804">Clin Cancer Res</pt> <yr title="Year" apt_id="805" id="yr_805">2019</yr>;<v title="Volume" apt_id="806" id="v_806">25</v>:<pages title="Pages" apt_id="807" id="pages_807">7497–505</pages>. <url title="URL" type="uri" href="https://doi.org/10.1158/1078-0432.CCR-19-0877" apt_id="808" id="url_808">https://doi.org/10.1158/1078-0432.CCR-19-0877</url> </jcit></bib><bib type="arabic" id="bib_809" sno="10" suffix="." apt_id="809"><othcit exinfo="journal" apt_id="810" id="othcit_810"><au apt_id="811" id="au_811"><s title="Surname" apt_id="812" id="s_812">Yazdani</s><f title="First name" apt_id="813" id="f_813">A</f></au>, <au apt_id="814" id="au_814"><s title="Surname" apt_id="815" id="s_815">Lenz</s><f title="First name" apt_id="816" id="f_816">HJ</f></au>, <au apt_id="817" id="au_817"><s title="Surname" apt_id="818" id="s_818">Pillonetto</s><f title="First name" apt_id="819" id="f_819">G.</f></au>, <etal title="etal" apt_id="820" id="etal_820">et al.</etal> <at title="Article Title" apt_id="821" id="at_821">Gene signatures derived from transcriptomic-causal networks stratified colorectal cancer patients for effective targeted therapy</at>. <pt title="Periodical Title" apt_id="822" id="pt_822">Reseach Square</pt> <yr title="Year" apt_id="823" id="yr_823">2023</yr>;:<pages title="Pages" apt_id="824" id="pages_824">rs–3</pages>.<query><button type="button" title="Copy Editor to Author-AU: Volume is missing in this reference [3]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="35" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">35</span></button></query></othcit></bib><bib type="arabic" id="bib_827" sno="11" suffix="." apt_id="827"><jcit apt_id="828" id="jcit_828"><au apt_id="829" id="au_829"><s title="Surname" apt_id="830" id="s_830">Das</s><f title="First name" apt_id="831" id="f_831">S</f></au>, <au apt_id="832" id="au_832"><s title="Surname" apt_id="833" id="s_833">Forer</s><f title="First name" apt_id="834" id="f_834">L</f></au>, <au apt_id="835" id="au_835"><s title="Surname" apt_id="836" id="s_836">Schönherr</s><f title="First name" apt_id="837" id="f_837">S.</f></au>, <etal title="etal" apt_id="838" id="etal_838">et al.</etal> <at title="Article Title" apt_id="839" id="at_839">Next-generation genotype imputation service and methods</at>. <pt title="Periodical Title" apt_id="840" id="pt_840">Nat Genet</pt> <yr title="Year" apt_id="841" id="yr_841">2016</yr>;<v title="Volume" apt_id="842" id="v_842">48</v>:<pages title="Pages" apt_id="843" id="pages_843">1284–7</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/ng.3656" apt_id="844" id="url_844">https://doi.org/10.1038/ng.3656</url> </jcit></bib><bib type="arabic" id="bib_845" sno="12" suffix="." apt_id="845"><jcit apt_id="846" id="jcit_846"><au apt_id="847" id="au_847"><s title="Surname" apt_id="848" id="s_848">Loh</s><f title="First name" apt_id="849" id="f_849">PR</f></au>, <au apt_id="850" id="au_850"><s title="Surname" apt_id="851" id="s_851">Danecek</s><f title="First name" apt_id="852" id="f_852">P</f></au>, <au apt_id="853" id="au_853"><s title="Surname" apt_id="854" id="s_854">Palamara</s><f title="First name" apt_id="855" id="f_855">PF.</f></au>, <etal title="etal" apt_id="856" id="etal_856">et al.</etal> <at title="Article Title" apt_id="857" id="at_857">Reference-based phasing using the Haplotype Reference Consortium panel</at>. <pt title="Periodical Title" apt_id="858" id="pt_858">Nat Genet</pt> <yr title="Year" apt_id="859" id="yr_859">2016</yr>;<v title="Volume" apt_id="860" id="v_860">48</v>:<pages title="Pages" apt_id="861" id="pages_861">1443–8</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/ng.3679" apt_id="862" id="url_862">https://doi.org/10.1038/ng.3679</url> </jcit></bib><bib type="arabic" id="bib_863" sno="13" suffix="." apt_id="863"><othcit exinfo="journal" apt_id="864" id="othcit_864"><au apt_id="865" id="au_865"><s title="Surname" apt_id="866" id="s_866">Steen</s><f title="First name" apt_id="867" id="f_867">CB</f></au>, <au apt_id="868" id="au_868"><s title="Surname" apt_id="869" id="s_869">Liu</s><f title="First name" apt_id="870" id="f_870">CL</f></au>, <au apt_id="871" id="au_871"><s title="Surname" apt_id="872" id="s_872">Alizadeh</s><f title="First name" apt_id="873" id="f_873">AA.</f></au>, <etal title="etal" apt_id="874" id="etal_874">et al.</etal> <at title="Article Title" apt_id="875" id="at_875">Profiling cell type abundance and expression in bulk tissues with CIBERSORTx</at>. <i apt_id="876" id="i_876">In</i> <pt title="Periodical Title" apt_id="877" id="pt_877">Methods Mol Biol</pt> <yr title="Year" apt_id="878" id="yr_878">2020</yr>;<pages title="Pages" apt_id="879" id="pages_879">135–57</pages>.<query><button type="button" title="Copy Editor to Author-AU: Volume is missing in this reference [24]. Please provide, if available." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="36" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">36</span></button></query></othcit></bib><bib type="arabic" id="bib_882" sno="14" suffix="." apt_id="882"><jcit apt_id="883" id="jcit_883"><au apt_id="884" id="au_884"><s title="Surname" apt_id="885" id="s_885">Yazdani</s><f title="First name" apt_id="886" id="f_886">A</f></au>, <au apt_id="887" id="au_887"><s title="Surname" apt_id="888" id="s_888">Mendez-Giraldez</s><f title="First name" apt_id="889" id="f_889">R</f></au>, <au apt_id="890" id="au_890"><s title="Surname" apt_id="891" id="s_891">Yazdani</s><f title="First name" apt_id="892" id="f_892">A.</f></au>, <etal title="etal" apt_id="893" id="etal_893">et al.</etal> <at title="Article Title" apt_id="894" id="at_894">Differential gene regulatory pattern in the human brain from schizophrenia using transcriptomiccausal network</at>. <pt title="Periodical Title" apt_id="895" id="pt_895">BMC Bioinf</pt> <yr title="Year" apt_id="896" id="yr_896">2020</yr>;<v title="Volume" apt_id="897" id="v_897">21</v>:<pages title="Pages" apt_id="898" id="pages_898">1–19</pages>. <url title="URL" type="uri" href="https://doi.org/10.1186/s12859-020-03753-6" apt_id="899" id="url_899">https://doi.org/10.1186/s12859-020-03753-6</url> </jcit></bib><bib type="arabic" id="bib_900" sno="15" suffix="." apt_id="900"><jcit apt_id="901" id="jcit_901"><au apt_id="902" id="au_902"><s title="Surname" apt_id="903" id="s_903">Ongen</s><f title="First name" apt_id="904" id="f_904">H</f></au>, <au apt_id="905" id="au_905"><s title="Surname" apt_id="906" id="s_906">Buil</s><f title="First name" apt_id="907" id="f_907">A</f></au>, <au apt_id="908" id="au_908"><s title="Surname" apt_id="909" id="s_909">Brown</s><f title="First name" apt_id="910" id="f_910">AA.</f></au>, <etal title="etal" apt_id="911" id="etal_911">et al.</etal> <at title="Article Title" apt_id="912" id="at_912">Fast and efficient QTL mapper for thousands of molecular phenotypes</at>. <pt title="Periodical Title" apt_id="913" id="pt_913">Bioinformatics</pt> <yr title="Year" apt_id="914" id="yr_914">2016</yr>;<v title="Volume" apt_id="915" id="v_915">32</v>:<pages title="Pages" apt_id="916" id="pages_916">1479–85</pages>. <url title="URL" type="uri" href="https://doi.org/10.1093/bioinformatics/btv722" apt_id="917" id="url_917">https://doi.org/10.1093/bioinformatics/btv722</url> </jcit></bib><bib type="arabic" id="bib_918" sno="16" suffix="." apt_id="918"><jcit apt_id="919" id="jcit_919"><au apt_id="920" id="au_920"><s title="Surname" apt_id="921" id="s_921">Yazdani</s><f title="First name" apt_id="922" id="f_922">A</f></au>, <au apt_id="923" id="au_923"><s title="Surname" apt_id="924" id="s_924">Lenz</s><f title="First name" apt_id="925" id="f_925">HJ</f></au>, <au apt_id="926" id="au_926"><s title="Surname" apt_id="927" id="s_927">Pillonetto</s><f title="First name" apt_id="928" id="f_928">G.</f></au>, <etal title="etal" apt_id="929" id="etal_929">et al.</etal> <at title="Article Title" apt_id="930" id="at_930">Gene signatures derived from transcriptomic-causal networks stratify colorectal cancer patients for effective targeted therapy</at>. <pt title="Periodical Title" apt_id="931" id="pt_931">Commun Med</pt> <yr title="Year" apt_id="932" id="yr_932">2025</yr>;<v title="Volume" apt_id="933" id="v_933">5</v>:<pages title="Pages" apt_id="934" id="pages_934">9</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s43856-024-00728-z" apt_id="935" id="url_935">https://doi.org/10.1038/s43856-024-00728-z</url> </jcit></bib><bib type="arabic" id="bib_936" sno="17" suffix="." apt_id="936"><jcit apt_id="937" id="jcit_937"><au apt_id="938" id="au_938"><s title="Surname" apt_id="939" id="s_939">Cho</s><f title="First name" apt_id="940" id="f_940">Y</f></au>, <au apt_id="941" id="au_941"><s title="Surname" apt_id="942" id="s_942">Rau</s><f title="First name" apt_id="943" id="f_943">A</f></au>, <au apt_id="944" id="au_944"><s title="Surname" apt_id="945" id="s_945">Reiner</s><f title="First name" apt_id="946" id="f_946">A.</f></au>, <etal title="etal" apt_id="947" id="etal_947">et al.</etal> <at title="Article Title" apt_id="948" id="at_948">Mendelian randomization analysis with survival outcomes</at>. <pt title="Periodical Title" apt_id="949" id="pt_949">Genet Epidemiol</pt> <yr title="Year" apt_id="950" id="yr_950">2021</yr>;<v title="Volume" apt_id="951" id="v_951">45</v>:<pages title="Pages" apt_id="952" id="pages_952">16–23</pages>. <url title="URL" type="uri" href="https://doi.org/10.1002/gepi.22354" apt_id="953" id="url_953">https://doi.org/10.1002/gepi.22354</url> </jcit></bib><bib type="arabic" id="bib_954" sno="18" suffix="." apt_id="954"><jcit apt_id="955" id="jcit_955"><au apt_id="956" id="au_956"><s title="Surname" apt_id="957" id="s_957">Cai</s><f title="First name" apt_id="958" id="f_958">J</f></au>, <au apt_id="959" id="au_959"><s title="Surname" apt_id="960" id="s_960">Su</s><f title="First name" apt_id="961" id="f_961">L</f></au>, <au apt_id="962" id="au_962"><s title="Surname" apt_id="963" id="s_963">Luo</s><f title="First name" apt_id="964" id="f_964">W.</f></au>, <at title="Article Title" apt_id="965" id="at_965">WD repeat domain 62 (WDR62) promotes resistance of colorectal cancer to oxaliplatin through modulating mitogen-activated protein kinase (MAPK) signaling</at>. <pt title="Periodical Title" apt_id="966" id="pt_966">Bioengineered</pt> <yr title="Year" apt_id="967" id="yr_967">2022</yr>;<v title="Volume" apt_id="968" id="v_968">13</v>:<pages title="Pages" apt_id="969" id="pages_969">14450–9</pages>. <url title="URL" type="uri" href="https://doi.org/10.1080/21655979.2022.2086381" apt_id="970" id="url_970">https://doi.org/10.1080/21655979.2022.2086381</url> </jcit></bib><bib type="arabic" id="bib_971" sno="19" suffix="." apt_id="971"><jcit apt_id="972" id="jcit_972"><au apt_id="973" id="au_973"><s title="Surname" apt_id="974" id="s_974">Bellenghi</s><f title="First name" apt_id="975" id="f_975">M</f></au>, <au apt_id="976" id="au_976"><s title="Surname" apt_id="977" id="s_977">Talarico</s><f title="First name" apt_id="978" id="f_978">G</f></au>, <au apt_id="979" id="au_979"><s title="Surname" apt_id="980" id="s_980">Botti</s><f title="First name" apt_id="981" id="f_981">L.</f></au>, <etal title="etal" apt_id="982" id="etal_982">et al.</etal> <at title="Article Title" apt_id="983" id="at_983">SCD5-dependent inhibition of SPARC secretion hampers metastatic spreading and favors host immunity in a TNBC murine model</at>. <pt title="Periodical Title" apt_id="984" id="pt_984">Oncogene</pt> <yr title="Year" apt_id="985" id="yr_985">2022</yr>;<v title="Volume" apt_id="986" id="v_986">41</v>:<pages title="Pages" apt_id="987" id="pages_987">4055–65</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/s41388-022-02401-y" apt_id="988" id="url_988">https://doi.org/10.1038/s41388-022-02401-y</url> </jcit></bib><bib type="arabic" id="bib_989" sno="20" suffix="." apt_id="989"><jcit apt_id="990" id="jcit_990"><au apt_id="991" id="au_991"><s title="Surname" apt_id="992" id="s_992">DiGuardo</s><f title="First name" apt_id="993" id="f_993">MA</f></au>, <au apt_id="994" id="au_994"><s title="Surname" apt_id="995" id="s_995">Davila</s><f title="First name" apt_id="996" id="f_996">JI</f></au>, <au apt_id="997" id="au_997"><s title="Surname" apt_id="998" id="s_998">Jackson</s><f title="First name" apt_id="999" id="f_999">RA.</f></au>, <etal title="etal" apt_id="1000" id="etal_1000">et al.</etal> <at title="Article Title" apt_id="1001" id="at_1001">RNA-seq reveals differences in expressed tumor mutation burden in colorectal and endometrial cancers with and without defective DNA-mismatch repair</at>. <pt title="Periodical Title" apt_id="1002" id="pt_1002">J Mol Diagn</pt> <yr title="Year" apt_id="1003" id="yr_1003">2021</yr>;<v title="Volume" apt_id="1004" id="v_1004">23</v>:<pages title="Pages" apt_id="1005" id="pages_1005">555–64</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.jmoldx.2021.01.008" apt_id="1006" id="url_1006">https://doi.org/10.1016/j.jmoldx.2021.01.008</url> </jcit></bib><bib type="arabic" id="bib_1007" sno="21" suffix="." apt_id="1007"><jcit apt_id="1008" id="jcit_1008"><au apt_id="1009" id="au_1009"><s title="Surname" apt_id="1010" id="s_1010">Hou</s><f title="First name" apt_id="1011" id="f_1011">X</f></au>, <au apt_id="1012" id="au_1012"><s title="Surname" apt_id="1013" id="s_1013">Xia</s><f title="First name" apt_id="1014" id="f_1014">J</f></au>, <au apt_id="1015" id="au_1015"><s title="Surname" apt_id="1016" id="s_1016">Feng</s><f title="First name" apt_id="1017" id="f_1017">Y.</f></au>, <etal title="etal" apt_id="1018" id="etal_1018">et al.</etal> <at title="Article Title" apt_id="1019" id="at_1019">USP47-Mediated deubiquitination and stabilization of TCEA3 attenuates pyroptosis and apoptosis of colorectal cancer cells induced by chemotherapeutic doxorubicin</at>. <pt title="Periodical Title" apt_id="1020" id="pt_1020">Front. Pharmacol.</pt> <yr title="Year" apt_id="1021" id="yr_1021">2021</yr>;<v title="Volume" apt_id="1022" id="v_1022">12</v>:<pages title="Pages" apt_id="1023" id="pages_1023">713322</pages>. <url title="URL" type="uri" href="https://doi.org/10.3389/fphar.2021.713322" apt_id="1024" id="url_1024">https://doi.org/10.3389/fphar.2021.713322</url> </jcit></bib><bib type="arabic" id="bib_1025" sno="22" suffix="." apt_id="1025"><jcit apt_id="1026" id="jcit_1026"><au apt_id="1027" id="au_1027"><s title="Surname" apt_id="1028" id="s_1028">Chen</s><f title="First name" apt_id="1029" id="f_1029">K</f></au>, <au apt_id="1030" id="au_1030"><s title="Surname" apt_id="1031" id="s_1031">Guo</s><f title="First name" apt_id="1032" id="f_1032">J</f></au>, <au apt_id="1033" id="au_1033"><s title="Surname" apt_id="1034" id="s_1034">Zhang</s><f title="First name" apt_id="1035" id="f_1035">T.</f></au>, <etal title="etal" apt_id="1036" id="etal_1036">et al.</etal> <at title="Article Title" apt_id="1037" id="at_1037">The role of dyslipidemia in colitis-associated colorectal cancer</at>. <pt title="Periodical Title" apt_id="1038" id="pt_1038">J Oncol</pt> <yr title="Year" apt_id="1039" id="yr_1039">2021</yr>;<v title="Volume" apt_id="1040" id="v_1040">1</v>:<pages title="Pages" apt_id="1041" id="pages_1041">6640384</pages>.</jcit></bib><bib type="arabic" id="bib_1042" sno="23" suffix="." apt_id="1042"><jcit apt_id="1043" id="jcit_1043"><au apt_id="1044" id="au_1044"><s title="Surname" apt_id="1045" id="s_1045">Dai</s><f title="First name" apt_id="1046" id="f_1046">H</f></au>, <au apt_id="1047" id="au_1047"><s title="Surname" apt_id="1048" id="s_1048">Liu</s><f title="First name" apt_id="1049" id="f_1049">C</f></au>, <au apt_id="1050" id="au_1050"><s title="Surname" apt_id="1051" id="s_1051">Li</s><f title="First name" apt_id="1052" id="f_1052">P.</f></au>, <etal title="etal" apt_id="1053" id="etal_1053">et al.</etal> <at title="Article Title" apt_id="1054" id="at_1054">Risk of dyslipidemia associated with VEGF/VEGFR inhibitors: a meta-analysis</at>. <pt title="Periodical Title" apt_id="1055" id="pt_1055">Translational Oncology</pt> <yr title="Year" apt_id="1056" id="yr_1056">2020</yr>;<v title="Volume" apt_id="1057" id="v_1057">13</v>:<pages title="Pages" apt_id="1058" id="pages_1058">100779</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.tranon.2020.100779" apt_id="1059" id="url_1059">https://doi.org/10.1016/j.tranon.2020.100779</url> </jcit></bib><bib type="arabic" id="bib_1060" sno="24" suffix="." apt_id="1060"><jcit apt_id="1061" id="jcit_1061"><au apt_id="1062" id="au_1062"><s title="Surname" apt_id="1063" id="s_1063">Prinz</s><f title="First name" apt_id="1064" id="f_1064">E</f></au>, <au apt_id="1065" id="au_1065"><s title="Surname" apt_id="1066" id="s_1066">Aviram</s><f title="First name" apt_id="1067" id="f_1067">S</f></au>, <au apt_id="1068" id="au_1068"><s title="Surname" apt_id="1069" id="s_1069">Aronheim</s><f title="First name" apt_id="1070" id="f_1070">A.</f></au>, <at title="Article Title" apt_id="1071" id="at_1071">WDR62 mediates tnfα-dependent JNK activation via TRAF2-MLK3 axis</at>. <pt title="Periodical Title" apt_id="1072" id="pt_1072">MBoC</pt> <yr title="Year" apt_id="1073" id="yr_1073">2018</yr>;<v title="Volume" apt_id="1074" id="v_1074">29</v>:<pages title="Pages" apt_id="1075" id="pages_1075">2470–80</pages>. <url title="URL" type="uri" href="https://doi.org/10.1091/mbc.E17-08-0504" apt_id="1076" id="url_1076">https://doi.org/10.1091/mbc.E17-08-0504</url> </jcit></bib><bib type="arabic" id="bib_1077" sno="25" suffix="." apt_id="1077"><jcit apt_id="1078" id="jcit_1078"><au apt_id="1079" id="au_1079"><s title="Surname" apt_id="1080" id="s_1080">Segawa</s><f title="First name" apt_id="1081" id="f_1081">R</f></au>, <au apt_id="1082" id="au_1082"><s title="Surname" apt_id="1083" id="s_1083">Shigeeda</s><f title="First name" apt_id="1084" id="f_1084">K</f></au>, <au apt_id="1085" id="au_1085"><s title="Surname" apt_id="1086" id="s_1086">Hatayama</s><f title="First name" apt_id="1087" id="f_1087">T.</f></au>, <etal title="etal" apt_id="1088" id="etal_1088">et al.</etal> <at title="Article Title" apt_id="1089" id="at_1089">EGFR transactivation is involved in TNF-α-induced expression of thymic stromal lymphopoietin in human keratinocyte cell line</at>. <pt title="Periodical Title" apt_id="1090" id="pt_1090">J Dermatol Sci</pt> <yr title="Year" apt_id="1091" id="yr_1091">2018</yr>;<v title="Volume" apt_id="1092" id="v_1092">89</v>:<pages title="Pages" apt_id="1093" id="pages_1093">290–8</pages>. <url title="URL" type="uri" href="https://doi.org/10.1016/j.jdermsci.2017.12.008" apt_id="1094" id="url_1094">https://doi.org/10.1016/j.jdermsci.2017.12.008</url> </jcit></bib><bib type="arabic" id="bib_1095" sno="26" suffix="." apt_id="1095"><jcit apt_id="1096" id="jcit_1096"><collab title="Collaborator" exinfo="author" apt_id="1097" id="collab_1097">GTEx Consortium Lead analysts</collab>. <at title="Article Title" apt_id="1098" id="at_1098">Genetic effects on gene expression across human tissues</at>. <pt title="Periodical Title" apt_id="1099" id="pt_1099">Nature</pt> <yr title="Year" apt_id="1100" id="yr_1100">2017</yr>;<v title="Volume" apt_id="1101" id="v_1101">550</v>:<pages title="Pages" apt_id="1102" id="pages_1102">204–13</pages>. <url title="URL" type="uri" href="https://doi.org/10.1038/nature24277" apt_id="1103" id="url_1103">https://doi.org/10.1038/nature24277</url> <query><button type="button" title="Copy Editor to Author-AU: Please note that the reference 'GTEx Consortium Lead analysts, 2017' is not mentioned (cited) in the text. Add it to the text and link it to the reference or delete it from the reference list by making changes directly in the text or references." contenteditable="false" query-type="open" roleid="12" froleid="12" troleid="14" conversation-uid="37" class="btn btn-outline-primary2 my-1 me-2 fw-bold btn-qry-reply" role="button">Q.<span class="badge" conversation-text="query">37</span></button></query></jcit></bib></ref></bm></doc>